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ABSTRACT

The urinary bladder is a musculomembranous sac which functions as a short term
reservoir for the urine produced in the kidneys. Various diseases including congenital
malformations (e.g., myelomeningocele) and postnatal diseases (e.g., bladder cancer) of
the lower urinary tract affect approximately 400 million people worldwide. Current
surgical treatments for these disorders rely on the use of autologous intestinal segments
and xenografts such as small intestinal submucosa, which suffer from various
complications including mechanical mismatch and graft shrinkage. Tissue engineering
approaches have been explored where the urinary bladder has been successfully engineered
in-vitro and implanted in humans by Atala and colleagues who reported successful
outcomes implanting collagen-PGA based tissue engineered neo-bladders in both dogs and
humans. However, Phase II clinical trials of the same approach by Tengion Inc. using the
autologous cell-seeded collagen-PGA/PLGA scaffold for patients suffering from
neuropathic bladders demonstrated multiple adverse events such as bowel obstruction and
bladder rupture, without improving capacity or compliance which resulted in
discontinuation of the study. Although the exact reason for this failure is still unknown,
flaws in scaffold mechanical properties and design as well as the use of autologous cells
from the diseased bladder may need to be reevaluated. Also, a recent comprehensive review
of bladder tissue engineering studies suggests that the technology needs further
improvement and evaluation through animal models of bladder dysfunction. Therefore, the
objective of this doctoral dissertation was to characterize a viable bladder tissue scaffold
(patch) which mimics the mechanical properties of the bladder, maintains the phenotype
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of the BSMC seeded in it and finally, tested in vivo in a dysfunctional bladder model to
evaluate its true efficacy.
In pursuit of this goal, firstly we explored the use of composite hydrogel blends
composed of Tetronic (BASF) 1107-acrylate (T1107A) in combination with extracellular
matrix (ECM) moieties collagen and hyaluronic acid seeded with bladder smooth muscle
cells (BSMC). The results of in vitro experiments demonstrated that the composite
hydrogel system provided an environment for bladder smooth muscle cells to adhere,
migrate and secrete ECM, thereby increasing the construct’s overall strength and
stiffness.
Second, we characterized various biodegradable elastomers as scaffolds for
bladder tissue engineering since the mechanical properties of our cell-seeded composite
hydrogels were limited after two weeks of culture. The comparison of mechanical
behaviors of these elastomeric scaffolds demonstrated that the PCUU scaffolds mimicked
urinary bladder mechanics more closely than PGS-PCL and PEUU. The PCUU scaffolds
exhibit relatively high compliance under low forces and are able to withstand stress
corresponding to 100 kPa (super physiological peak stress experienced by urinary
bladders in vivo) and thus, possess the strength and stiffness necessary to be used as a
urinary bladder tissue engineering scaffold. The PCUU scaffolds also showed cytocompatibility as well as increased porosity with increasing stretch indicating its ability to
aid in infiltration of smooth muscle cells.
Thirdly, the BSMC-seeded PCUU scaffold was subjected to uniaxial mechanical
stretch mimicking bladder cycling using our custom-made bioreactor under standard cell
iii

culture conditions (37 °C, humidified, 5% CO2 / 95% air). When subjected to uniform and
continuous uniaxial stretch (1.25-1.75), the BSMC-seeded PCUU scaffolds did not
undergo permanent deformation in spite of high stretch and indicated its suitability to be
used in vivo. We demonstrated that coating the PCUU scaffolds with fibronectin and gelatin
using the layer-by-layer method enhanced BSMC adhesion and infiltration into the
scaffold, which was necessary for continued adhesion of the BSMC under mechanical
stretch. The study has completed calibration of the custom bioreactor for future studies to
characterize the in vitro response of BSMC seeded on PCUU scaffolds to conditions
mimicking bladder cycling.
Finally, we attempted at implanting the PCUU scaffolds onto a bladder outlet
obstruction (BOO) rat model to create a clinically informative study. The BOO bladders
tend to exhibit overactive bladder symptoms with high pressure and voiding frequency
and, if untreated, could often lead to death of the rats due to vesicoureteral reflex. The
PCUU augmentation led to the enhanced survival of the rats (66.66%) and increased
bladder capacity and voiding volume with time, indicating that the high-pressure bladder
symptom was alleviated. The histological analysis of the explanted scaffold indicated
some smooth muscle cell and connective tissue infiltration, but also calcium deposits. We
hypothesize that ECM-coating and pre-seeding PCUU scaffolds with cells can aid in
promoting faster scaffold integration into the host bladder. Due to inherent tendency of
stone formation in rat models, future studies may switch to using dysfunctional bladder
models of larger animal like pigs. However, the present study is one of the first to analyze
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a synthetic bladder scaffold using a bladder dysfunction model in rats for application in
urinary bladder tissue engineering.
In summary, the present study characterized composite hydrogel and elastomeric
scaffolds for bladder tissue engineering applications. Based on the results of in vitro
mechanical characterization and cell culture studies, we concluded that PCUU scaffolds
was most relevant scaffold for bladder tissue engineering among the ones we examined.
For the first time, we used an established rat model for studying bladder dysfunction
(BOO) to evaluate the effect of augmentation of the bladder with PCUU scaffolds on
bladder capacity and voiding volume. The knowledge gained in the present study will
work towards future improvement of bladder tissue engineering technology to ultimately
aide in the treatment of bladder disorders.
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Chapter 1
INTRODUCTION AND BACKGROUND
Urinary Bladder Anatomy
The urinary bladder is a hollow, distensible musculomembranous sac that lies in
the pelvic cavity just posterior to the symphysis pubis (1, 2). It functions as a short-term
reservoir for the urine produced by the kidneys. Under normal conditions, the human
bladder has a capacity to store approximately 500 ml of urine although progressive
sensation of fullness and desire to void are experienced when the volume reaches around
300ml. As it fills the bladder expands up to fifteen times its contracted size assuming an
ovoid shape. During voluntary micturition, smooth muscle of the bladder contracts while
sphincter muscles of the urethra relax to allow releasing of the content.
The bladder wall tissue is composed of four distinct layers, namely the
urothelium, lamina propria, detrusor, and serosal layer (Figure 1-1). The mean bladder
wall thickness measured from the urothelium to serosa in adult humans is approximately
3.3 ± 1.1 mm for males and 3.0 ± 1 mm for females, respectively (3). The unique features
of the bladder, the large capacity and high compliance, are due to the highly specialized
properties of the urothelial lining and the smooth muscle wall of the bladder (4).
Urothelium
The urothelium is a specialized type of epithelium called the transitional
epithelium. The cells in the layer have the ability to slide past one another and the
number of cell layers decreases as the volume of the urinary bladder increases (2). The
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urothelium plays a major role in maintaining the composition of urine akin to that
generated by the kidneys. This is achieved via four unique features of the urothelium.
First, the tissue offers a minimum surface area to urine for passive permeability of
substances between blood and lumen. Second, the passive permeability of the tight
junction between cells and apical cell membrane to electrolytes and non-electrolytes is
also very low. Third, hormonally regulated absorptive system of the urothelium regulates
sodium absorption to counter the passive movement of sodium from blood to urine. Last,
all of these permeability properties of the urothelium are unaffected by most substances
found in blood or urine, and, thus, the composition of urine stays constant (5).

Figure 1-1: Tissue layers of the urinary bladder.
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Lamina Propria
Lamina propria is a collagenous connective tissue (4) that functions to maintain
the shape of bladder wall and to limit its overall compliance (ratio of maximum volume
divided by pressure). This layer is approximately 1.3 mm thick in humans and supports
various cell types, and the entire bundle of capillary network is embedded in it (4). The
lamina propria is composed mainly of dense irregular connective tissue, fibroblasts, and a
thin smooth muscle muscularis mucosa (6) .
Detrusor and Serosal Layers
The detrusor muscle layer plays a major role in the voiding of urine by
contraction (7). Detrusor wall thickness in humans is approximately 1.4 mm for males
and 1.2 mm for females (8). This layer is mainly composed of coarse bundles of smooth
muscle fibers (9), (10). The muscle fibers form branching, interlacing bundles loosely
arranged into inner longitudinal, middle circular, and outer longitudinal layers(11) .
However, in the upper aspect of the bladder, these layers are clearly not separable, and
any one fiber can travel between each of the layers, change orientation, and branch into
longitudinal and circular fibers. This meshwork of detrusor muscle is ideally suited for
emptying the spherical bladder (11). The individual smooth muscle fibers in these
bundles run parallel to one another and are generally 1-2 µm in diameter. The muscle
bundles have a diameter of 50–150 µm and the interfascicular space between the bundles
is usually between 20-50 µm. Within the interfascicular space, capillaries and larger
blood vessels are observed (9).The detrusor layer is surrounded by the serosal layer,
3

which is a dense layer of fine collagen fibrils that are straight and uniform and are not
interspersed with blood vessels (4, 9).

Pathological Conditions of the Urinary Bladder Requiring Repair and
Reconstruction
Approximately 400 million people worldwide are affected by various diseases of
the urinary bladder that require repair and reconstruction (12). This figure includes, but is
not limited to, congenital malformations of the lower urinary tract such as bladder
exstrophy (part of the bladder is present outside the body and the pelvic bones are
separated), myelomeningocele (spine does not close before birth), or posterior urethral
valves (obstructing membrane in the posterior male urethra)(13). Additionally,
postnatally acquired diseases such as chronic interstitial cystitis (characterized by
frequent and painful urination and/or pain in the bladder and pelvic region), neurogenic
bladder (characterized by difficulty in storing or voiding urine), bladder fibrosis and
cancer (among the 10 most common cancers) amount to critical need of surgical
replacement and repair (12).
Current treatments to congenital malfunctions and bladder fibrosis involve
surgical augmentation of the bladder, which often requires a second surgery to
reconstruct surrounding bones and soft tissues (11, 14-17) . In contrast, the neurogenic
bladders may be initially treated with medicines to activate or relax the bladders, or
through exercise to strengthen the pelvic muscles (18-20). However, if the problem
becomes severe the neurogenic bladders are emptied by intermittent or permanent
4

catheterization and surgical approaches such as artificial sphincter, sling surgery, or
electrical stimulation of the sacral nerve may be adopted (18-20). Similarly, interstitial
cystitis is treated mainly via medication, and surgical interventions (e.g., supratrigonal
cystectomy and cystourethrectomy) are reserved as a last resort (21). Bladder cancer, on
the other hand, is routinely treated surgically with a variety of techniques such as partial
or radical cystectomy in combination with radiation therapy, chemo therapy,
immunotherapy depending on the patient and the stage of the disease (22, 23), (24, 25).
While a number of urological complications are surgically treated, conventional
modes of treatment for bladder repair suffer from several limitations. One of the common
risks for treatment of urinary bladder disorders are urinary tract infections and
incontinence (14-21). Apart from that, many treatment methods suffer from specific
risks: sexual dysfunction in the case of surgery for exstrophy (16, 17); meningitis,
hydrocephalus and loss of bladder control in the case of surgery of myelomeningocele
(15); renal failure and vesicoureteral reflex in the case of posterior urethral valve
treatment (14); and chronic urine leakage and kidney damage in the case of neurogenic
bladders (18-20). Treatment for bladder cancer also can lead to the risk of anemia,
swelling of the ureters and urethral strictures (22-26).

Current Approaches in Bladder Repair
Currently, materials used in surgical repair to treat various complications of the
urinary bladder include autografts, allografts and xenografts, which have exhibited
varying successes and problems as reviewed in the following sections.
5

Use of Autologous Tissues in Cystoplasty
Cystoplasty is one of the most common approaches to treat patients who lack
adequate bladder capacity or detrusor compliance. Abnormal compliance or decreased
bladder capacity may manifest as debilitating urgency, frequency, incontinence, recurrent
urinary tract infections (UTIs), pyelonephritis, or progressive renal insufficiency. For
many patients, augmentation cystoplasty can provide a safe functional reservoir that
allows for urinary continence and prevention of upper tract deterioration (27). These
problematic bladders have been conventionally treated using segments of autologous
natural tissue such as omentum, peritoneum, ureters and most commonly, a portion of the
large intestine (enterocystoplasty) (28). The procedure aims to improve bladder capacity
in severely contracted bladders with compliant and vascularized tissues (4). However,
enterocystoplasty has been known to generate various long-term complications that
include mucus production by the bowel epithelium, stone formation, bacteriuria,
metabolic disturbances, malignancy, and intestinal complications (4, 26). These
complications of enterocystoplasty may result from the fact that, the intestinal epithelium
is neither structurally, nor physiologically adapted to prolonged exposure to urine (29).
Since the side effects of enterocystoplasty were considered due to the interaction
of urine with the bowel mucosa, numerous animal model studies have been performed to
expose the raw muscle surface to urine after the removal of the bowel epithelium and
examined the effects of de-epithelialization (4). However, contrary to expectations, the
results of these studies provided evidence of graft shrinkage and fibrosis, severe
inflammation, infection, and ischemia (30) all of which underscored the importance of
6

epithelial tissue. Although complete elimination of these problems was not achieved, two
major studies using a porcine model have demonstrated so far that fibrosis and shrinkage
of the implanted grafts were minimized by covering the augmenting graft with
autologous human urothelium (31, 32). The first study used autologous urothelial cells
isolated at hemicystectomy and sprayed onto demucosalised colon, which was then
incorporated into the remaining bladder. After 6 weeks, the presence of uroplakinpositive urothelium was observed on top of a bladder or colonic smooth muscle
submucosa and no inflammation was described (31). In another study, in vitro–
propagated autologous urothelial cells were implanted onto a vascularised, deepithelialized uterine tissue used as the augmenting segment in a “composite cystoplasty”
(32). However, there was evidence of stromal inflammation within both augmented and
native segments along with incomplete urothelialisation leading to poor urinary barrier
properties. Based on these findings, the authors hypothesized that implanting
“differentiated” urothelium would lead to rapid establishment of an effective urinary
barrier and would provide the stroma with immediate protection form urine-mediated
damage (32). However, enterocystoplasty as a technique still suffers from problems such
as substantial graft shrinkage, and, thus, alternatives are being sought to replace this
technique.
Another approach of bladder repair using the patient’s own tissue is
ureterocystoplasty, which exploits the use of urothelium derived either from a grossly
dilated ureter or from the bladder itself after excising the overlying detrusor muscle (33).
While it is a clinically proven concept and the use of autologous urothelial tissues can
7

eliminate many, if not all, of the complications associated with enterocystoplasty, this
approach is confined to a small minority of patients with gross ureteric dilatation.
Moreover, studies have demonstrated that it is not suited to small or trabeculated
bladders, which are commonly encountered in neuropathic dysfunction (33), (29). These
shortcomings of the currently available techniques of cystoplasty have led clinicians and
researchers to turn to alternative biomaterials (e.g., free tissue grafts and decellularized
matrices) for bladder repair.

Free Tissue Graft
A free tissue graft is a section of tissue detached from its blood supply, moved to
another part of the body, and reattached by microsurgery to a new blood supply (34).
This is unlike cystoplasty described above, which retain its own blood supply during
transfer to site of repair. A number of attempts have been made to incorporate various
types of free human tissues including muscle flaps, split skin grafts, placenta, peritoneum,
and dural membrane into the bladder in the form of patches (4). The results to date have
been mixed, ranging from graft contraction and stone formation to hair growth on grafts
derived from skin (4).

Muscle Flap as Bladder Wall Substitute
An animal model study compared rectus abdominis and musculo-peritoneal
(rectus abdominis with overlying peritoneum) flaps used as urinary bladder wall
substitutes in rats (35).The quality of urothelium and smooth muscle layer regenerated
8

with the detrusor myectomy (incorporation of skeletal muscle) was similar in both groups
at the end of six and ninety days indicating that the rectus abdominis muscle alone
sufficed as a matrix for the bladder wall. Although both cases presented urolithiasis, this
was attributed to the non-absorbable sutures used in the surgery and to the rat model
which is prone to stone formation.
The efficacy of detrusor myectomy was also demonstrated by another study using
a canine model of hematuria and stranguria, which revealed that when the rectus
abdominis muscle flap was surgically sutured to the defective bladder; the dog
maintained normal health and showed no signs of urinary incontinence even after a
period of two and a half years (36). Neither caliculi nor stricture or scarring was visible in
the abdominal radiographs (36). Though the study was based on only one specimen, the
study shows promise and further research to confirm these findings would aid in the use
of rectus abdominis muscle flap for bladder repair purposes.

hAM
The Human amniotic membrane (hAM) is an avascular tissue that forms the inner
layer of the fetal membranes (37). Since hAM is normally disposed of after parturition it
can be readily available for research use with few ethical concerns. To determine the
efficacy, bladder augmentation in rats using hAM was performed and the results were
compared after 3 and 6 months post-operatively (37). Rats that received partial
cystectomy with primary closure without an implant served as the control. The authors
reported that the hAM-reconstructed bladder wall displayed all three major (mucosal,
9

muscular, and serosal) layers of the bladder wall as well as nerve ﬁbers although nerve
and smooth muscle bundles were sparser and smaller compared to control groups. In
addition, very few inflammatory cells were observed after 3 months, suggesting the
absence of rejection. While no obvious graft shrinkage was observed, bladder calculi
were found in 8 of the 18 rats (44%) in the hAM group at 6 months (37). When tested in
vitro, regenerated bladder strips exhibited noticeable contractile responses to a
muscarinic receptor agonist and to electrical field stimulation. The contractile responses
by hAM bladder strips were, however, very low compared to those of the control bladder
strips even after six months indicating immature tissue development. Although hAM
exhibits a number of positive features, the use of hAM as a bladder tissue substitute is
very limited since it cannot be mass-produced or obtained in an off-the shelf manner for
all cases.

Decellularized Matrices
SIS
Decellularized xenogeneic or allogeneic matrices prepared from the submucosa of
small intestine and bladders have been tested in the surgical treatment of the urinary
bladder and other tissues (29). Small intestinal submucosa (SIS) is a collagenous
membrane derived from porcine small intestines (Figure 1-2) which was first described
by Badylak et al. (38).The tunica mucosa, serosa and tunica muscularis are mechanically
removed from the inner and outer surfaces of the intestinal wall to leave a 0.1-mm
collagen-rich membrane largely composed of the submucosal layer (39). The early
10

studies demonstrated that, when incorporated in the urinary bladder of rats, SIS allowed
not only rapid cellular encroachment and infiltration, but also vascularization and reinnervation (40). SIS degrades completely in the body within a period of four to eight
weeks and its byproducts are excreted via the urine (41). Although the bladder repairing
approach using SIS allowed post-surgical regeneration of tissue that exhibited all three
layers of the normal bladder (41), several unwanted outcomes have been noted. For
example, when implanted in dogs the regenerated bladders often exhibited a higher
collagen to muscle ratio than normal bladders and its long-term clinical implications have
not been fully understood (41).These SIS-based bladder grafts have also shown fibrosis
and reduced smooth muscle contraction (29). Moreover, the regenerative potential of SIS
was dependent on the age of the donor and the portion of the intestine from which the SIS
matrices are derived (4). An animal study provided evidence that SIS derived from pigs
older than 3 years old exhibited consistent bladder regenerative results compared to SIS
derived from younger pigs (42). In addition, the same study revealed that bladder
regeneration is more reproducible with SIS from distal segments than from proximal
segments of the ileum (42).While these studies have provided valuable information and
demonstrated the feasibility of decellularized matrices as a bladder repair material, these
limitations have prevented SIS from being considered as an ideal implant to aid in
effective bladder regeneration and remodeling.

11

Figure 1-2: A sheet of small intestinal submucosal scaffold.

BAM
Bladder acellular matrix graft (BAM) is another type of decellularized tissue
matrix which has shown to support regeneration of the bladder in vivo. Following partial
cystectomy and after 22 weeks of implantation, the BAM-augmented bladder exhibited
urothelial and muscle layers with reinnervation and revascularization in porcine models
(43). Histological analysis of excised BAM revealed that four major components of the
extracellular matrix, type I and type IV collagen, elastin, laminin, and fibronectin were
present in the matrix (44), (43) and similar results were in canine and murine models(4).
Although many of the results have been positive, it has been reported that BAM also
exhibit problems seen with SIS, namely, lithogenesis, graft shrinkage, and incomplete
and disorganized smooth muscle infiltration (4). Moreover, despite the stringent
decellularization process (with a series of hypotonic buffer solutions and various
detergents), remnants of cellular components have been identified within BAM (45) ,
which may lead to an immunogenic reaction when implanted into the body. Thus, further
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improvement in processing and pre-treatment may be necessary for BAM to be used
successfully in bladder tissue regeneration.

Current Research in Bladder Tissue Engineering
Because of the various complications associated with auto-, allo-, and xeno-grafts,
the alternative approaches are being sought in the direction of tissue engineering. This
involves seeding appropriate autologous cells onto scaffolds to form live, implantable
tissue constructs. The biomaterials used for scaffolds may be either synthetic polymers or
naturally occurring materials. While synthetic polymer allows for controlling various
parameters such as mechanical properties and pore architecture, natural biomaterials have
many inherent advantages which include the presence of native growth factors, a
naturally occurring architecture, and the presence of ubiquitous extracellular elements
(45).The following subsections will review the current research in the field of bladder
tissue engineering.

Clinical Success of Bladder Tissue Engineering
Since the advent of the term and concepts of tissue engineering in the early
1990’s, the bladder has been one of the few organs that have been synthesized in vitro
and successfully implanted. Atala and colleagues were the first group to report such
seminal work on tissue engineered neo-bladders in both dogs and humans (13, 46). The
biomaterial used for the scaffolds was polyglycolic acid (PGA) coated with poly-DLlactide-co-glycolide 50:50 (PLGA) and the implant was wrapped with the hosts’
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omentum (a fatty tissue layer under the peritoneum) in both cases (13, 46). Briefly, after a
trigone-sparing cystectomy, one group of beagle dogs underwent closure without a
reconstructive procedure; the second group underwent reconstruction with cell free
scaffolds, and the third group received scaffolds seeded with autologous urothelial cells
on the luminal surface and smooth muscle cells on the exterior surface. The results of this
animal study clearly showed structural and functional differences among the three
experimental groups 11 weeks post-surgery (46). The animals that received no implant
gained a minimal increase while the non-seeded bladders exhibited a slight increase in
reservoir volume over time. Although these non-seeded scaffolds developed an intact
urothelial layer, the smooth muscle layer was deficient and fibrotic resulting in low
compliance (46). In contrast, the cell-seeded neo-bladders exhibited capacities and
compliance greater than the pre-cystectomy level (46). The retrieved tissues displayed a
normal cellular organization, consisting of a trilayer of urothelium, submucosa, and
muscle with innervation (46).
The group then investigated tissue engineered bladder augmentation in humans
with end-stage bladder diseases needing cystoplasty (13). The study involved seven
patients suffering from myelomeningocele, aged 4-19 years with high pressure or poorly
compliant bladders. Urothelial and smooth muscle cells were obtained from a bladder
biopsy from each patient and expanded in culture for seven weeks prior to seeding. The
neo-bladder recipients were categorized based on three types of constructs; a
homogenous decellularized bladder submucosa scaffold, a cell seeded collagen matrix
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implant wrapped with omentum, and a collagen-PGA composite implant wrapped with
omentum (Figure 1-3).

Figure 1-3: Construction of engineered bladder. Scaffold seeded with cells (B)
engineered bladder anastomosed to native bladder with running 4–0 polyglycolic sutures
(C) Implant covered with fibrin glue and omentum.

While all three types of bladders displayed low intravesical pressure (below 40
cm H2O) and stable renal functions post-operatively, the collagen-PGA composite
scaffolds with omentum wrapped exhibited the greatest bladder capacity and compliance
(13). Moreover, immunohistochemical analyses of biopsy tissues revealed that smooth
muscle and urothelial cells within the regenerated bladder constructs were phenotypically
normal.
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Figure 1-4: Cystograms and urodynamic findings in a patient with a collagen-PGA
scaffold engineered bladder (A) Preoperative and (B) 10-month postoperative

The results of this seminal study demonstrated that the abnormally high bladder
pressure before the operation clearly improved 10 months after implantation of the neobladder that was composed of cell-seeded collagen-PGA scaffold and the patient’s
omentum (Figure 1-4). Although these studies demonstrated the feasibility of bladder
tissue engineering, several issues are still unresolved. For example, the success of the
bladder augmentation was limited and seems to depend on the presence of omentum,
which may or may not be available in all patients needing bladder replacement. Also,
Studies by Eberli et al. have shown that Collagen-PGA composite scaffolds possessed
twice the stiffness (Young’s modulus ~0.001 MPa) compared to native bladder tissue
(Young’s modulus ~0.002MPa) (47).
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In-Vitro Cell Studies of Cell-Biomaterial Interactions
Although initial trials of bladder tissue engineering have met with some success, a
number of basic scientific questions remain unanswered. For example, the choice and
designs of scaffold materials are known to influence the behavior of seeded cells, which
must be carefully examined and controlled prior to implantation of the engineered tissue
constructs. The following subsections review the current in vitro work on cell-biomaterial
interactions.
Bladder Cell Interactions with Polyesters
To date, a number of synthetic polymers have been studied as potential scaffold
materials for engineering of the urinary bladder. The advantages of these synthetic
materials are that they can be manufactured rapidly in a large scale and can be processed
to obtain desired levels of strength, microstructure, and degradation rate. In addition,
some of the synthetic polymers (e.g., poly lactic acid (PLA), poly glycolic acid (PGA),
poly (lactic-co-glycolic acid) (PLGA) and poly caprolactone (PCL)) have been approved
by the US food and drug administration (FDA) for use in medical devices, and thus, do
not require additional regulatory compliance assessments prior to use in clinical
applications.

17

Figure 1-5: Basic structure of poly (lactic-co-glycolic acid) (PLGA). In this figure;
‘X’ represents the number of units of lactic acid and ‘y’ represents the number of units of
glycolic acid.

Applicability of these polyesters to bladder tissue engineering was assessed by
examining the influence of physical properties of PCL (Figure 1-6) and PLGA (Figure 15) films on the growth of normal human urothelial (NHU) and bladder SMC in vitro (48)
,(49). More specifically, two types (high and low elastic moduli) of PLGA and PCL films
were compared with standard tissue culture plastic (control). The cell growth of both
NHU and SMC on the low modulus PLGA films was greater than that on the high
modulus films at 24, 48, and 72 hour time points. A similar trend was observed for the
SMC growth on PCL films; a greater number of cells were present on lower modulus
films at 72 hour and 7 day time points (48). Together, these results demonstrate that the
elastic modulus of the scaffold material is a critical parameter for the proliferative
response by the bladder cells seeded.
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Figure 1-6: Basic structure of polycaprolactone (PCL)
The effect of mechanical properties of polyester scaffolds was further investigated
in a 3-D environment by culturing human urinary tract stromal cells on PLGA and PCL
foams prepared by emulsion freeze-drying (49). The stromal cells on PCL scaffolds
exhibited a 4.4-fold higher attachment and 2.4-fold higher rate of proliferation compared
to the stromal cells cultured on PLGA scaffolds after a period of seven days. Since the
storage modulus of PCL (2MPa) is half of that of PLGA and is closer to the storage
moduli value for native bladder tissue (0.25 MPa (50)) (49), the authors concluded that
cell attachment and proliferation were enhanced by the high compliance nature of PCL
(49). Thus, based on the results from these 2D and 3D studies, the PCL may be a better
candidate material than PLGA in bladder tissue engineering applications although a
number of other parameters have yet to be examined.

Bladder Cell Interactions with SIS
To demonstrate the efficacy of SIS in use for bladder augmentation, Kropp and
colleagues performed a series of studies using cell-seeded and non-seeded SIS (42), (39,
51). Specifically, SIS was evaluated in-vitro after seeding it with human urothelial and
smooth muscle cells (passages between 2 and 8) at a density of 1 x 105 cells per cm2 in
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five different configurations (39). The culture configurations that were evaluated were (1)
urothelial cells seeded alone on the mucosal surface of SIS, (2) smooth muscle cells
seeded alone on the mucosal surface, (3) layered co-culture of smooth muscle cells
seeded on the mucosal surface followed by urothelial cells 1 hour later, (4) sandwich coculture of smooth muscle cells seeded on the serosal surface followed by seeding of
urothelial cells on the mucosal surface 24 hours later, and (5) mixed co-culture of
urothelial cells and smooth muscle cells seeded together on the mucosal surface. Four
weeks after cell seeding, it was seen that a layered and sandwich co-cultures exhibited
smooth muscle cell invasion of SIS, organized cell sorting, and formation of well-defined
urothelium, which were not seen with cultures of smooth muscle or urothelial cells alone
(39).The mixed co-culture exhibited no evidence of cell sorting either, though it exhibited
smooth muscle penetration of SIS matrix (39). Their results suggest that establishment of
cell-to-cell communications between identical cell types (i.e., SMC-SMC, urothelialurothelial) seeded as separate layers may be a requisite for formation of distinct layers in
neo-bladders engineered with SIS.

Stem Cell Differentiation into SMC on PEG Hydrogel Scaffolds
Hydrogels are a class of highly hydrated polymer materials (water content > 30%
by weight) which are composed of hydrophilic polymer chains. The major advantages of
using hydrogels are that they can be processed under relatively mild conditions (general
absence of toxic chemicals in synthesis) and have structural and mechanical properties
similar to the ECM (52). One of the common hydrogels used in soft tissue engineering
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applications is polyethylene glycol (PEG), which is prepared by polymerization
of ethylene oxide and is commercially available over a wide range of molecular weights
from 300 Da to 10,000 kDa (52), (53). Since PEG undergoes limited metabolism in the
body, only PEGs with molecular weight less than 50 kDa are considered in tissue
engineering application as they can be completely eliminated from the body (via the liver
and kidney)(54). PEG has many advantageous characteristics which are essential for
tissue engineering application. They are hydrolytically non-degradable polymers with
excellent solubility in water and many other organic solvents. Melting points of the
different PEG derivatives are dependent on the molecular weight of the chain and this
property can be exploited to manipulate the mechanical properties of polymers applied at
room temperature (Figure 1-7). PEG can form highly hydrated polymer coils on the
biomaterials surface which can effectively be used to repel proteins. This property can be
used to from inert polymer surfaces and non-fouling coatings to prevent bacterial growth
or cellular adhesion on biomaterial surfaces. The terminal functional groups of PEG can
be co-polymerized with various polymers and this property can also be used to
manipulate its degradability (54).

Figure 1-7: Structure of poly (ethylene glycol) (PEG).
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Toward bladder tissue engineering applications, the differentiation of human
mesenchymal stem cells (MSC) cultured on 3D PEG hydrogel scaffolds into SMC-like
cells was examined by Adelow and colleagues (55). More specifically, PEG hydrogel
was modified with an adhesive peptide, arginine-glycine-aspartic acid (RGD) for stem
cell attachment and matrix metalloproteinase- (MMP-) degradable peptides for enzymatic
degradation of the matrix for cell infiltration. The human MSC from bone marrow
(300,000 cells per scaffold with 2.3 cm diameter) were seeded on the hydrogel scaffolds
Cell viability, spreading, and proliferation as well as key functional marker expression
were assessed at various time points up to 21 days after hydrogel formation. The authors
reported that both MSC and SMC within the 3D hydrogel exhibited the elongated,
spindle-like morphology indicative of the contractile phenotype after two weeks in
culture. The resulting cells in the 3D PEG hydrogels exhibited up-regulation of markers
associated with the less synthetic, but more contractile phenotype of smooth muscle cells,
and increased cell proliferation compared to cells grown in 2-D culture (55). These
results demonstrated that strategic functional regulation of bladder SMC can be achieved
using PEG hydrogel, which may serve as ideal scaffolds to regenerate bladder tissue.
Application of Nanotechnology to Bladder Tissue Engineering
Among the limitations with use of synthetic materials in bladder tissue
engineering is the mechanical property mismatch between the polymers and tissues as
well as the lack of biological recognition of polymer surface by the host cells. To address
these issues, application of nanotechnology has been proposed as it has been shown to
promote cell growth and tissue development through appropriate designing of the inner
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architecture of the scaffolds (45). For example, several groups (56-58) have studied nanostructured synthetic materials as bladder tissue replacements and demonstrated that
increased surface roughness (at the nanometer and submicron levels) improved the
adsorption of select proteins important for bladder cell functions. In theory, the surfaces
of these nanomaterials offer a favorable environment for cell growth as they mimic the
natural environment of the bladder. This is because it has been reported that the
extracellular matrix proteins in bladder tissue are nanodimensional (28). This idea was
tested in an in vitro study that examined human smooth muscle cell function on PLGA,
PCL, and polyurethane (PU) films with nanodimensional surface features in a range of
50–100 nm (created using chemical etching techniques via NaOH and HNO3
soaking)(56). In comparison with the cells cultured on micron or submicron surfaces,
bladder smooth muscle cells cultured on nanosurfaces exhibited greater elastin synthesis
and collagen production indicating that the difference in surface textures indeed
influenced bladder cell behavior (56). This was further confirmed by a study using 3D
nanotextured PLGA and PU scaffolds, which also demonstrated greater elastin and
collagen production by bladder smooth muscle cells compared to conventional
nanosmooth polymers (57).
However, these results with bladder smooth muscle cells did not agree completely
with other in vitro studies using rat PC12 adrenal medulla cells, which demonstrated that
nanometer surface features alone did not inﬂuence cell proliferation, unless serum
proteins are present in the cell culture media (59), (60). Taken together and applying this
principle to bladder SMC, it can be hypothesized that the adsorption of select soluble
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proteins to the substrate surface is essential for enhanced bladder smooth muscle cell
function (58). To date, however, most of the studies using nano-structured materials have
focused on in vitro assessment and not been subjected in vivo testing for regeneration of
bladder. Further study, therefore, is needed to evaluate the true efficacy of
nanotechnology in bladder tissue engineering.

Effects of Mechanical Force Stimuli on Bladder Tissue Engineering
Since the urinary bladder is subjected to different mechanical forces during filling
and emptying, it has been postulated that subjecting bladder cells and cell-seeded
scaffolds to relevant mechanical forces in vitro may be beneficial for bladder tissue
regeneration. For example, an in-vitro study demonstrated penetration of rat bladder
smooth muscle cells in SIS along with de novo synthesis of collagen and elastin by these
seeded cells when the matrices were subjected to both chemical and mechanical stimuli
for 2 weeks (61). Briefly, the elastin synthesis by SMC seeded on SIS was significantly
greater when they were subjected to 15% cyclic stretch at a frequency of 0.1 Hz
compared to the cells subjected to stretch at 0.5Hz or maintained under static conditions.
In addition, collagen synthesis, cell proliferation, and migration into SIS by SMC were
greater when exposed to cyclic stretch in the presence of VEGF (10 ng/ml) compared to
that in the absence of VEGF (61). Although application of mechanical force and
incorporation of growth factors enhanced the synthetic functions of SMC, their effects on
the contractile markers remain unknown. This was addressed by another study that
examined the effects of sustained tension on rat bladder SMC in 3D collagen gel culture
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(62). More specifically, compared to the cells of no tension control, SMC that were
subjected to sustained tension inside the collagen gel exhibited significantly greater
expression of α-smooth muscle actin and elongated cell morphology, both of which
indicated enhanced contractile phenotype (62). Together, the results of these studies
suggest that mechanical and chemical cues may be just as important as scaffold material
selection for bladder tissue engineering.

In vivo Animal Studies in Bladder Tissue Engineering
Application of SIS in tissue engineering
Motivated by the success of in-vitro results, further studies were conducted to
evaluate the performance of cell-seeded vs. unseeded SIS in vivo (51). Human SMC and
urothelial cells were seeded on SIS in a layered co-culture fashion and were implanted
subcutaneously in nude mice (unseeded SIS was implanted as control). These grafts were
then harvested at 4, 8 and 12 weeks after implantation. Evaluation of cell-seeded grafts at
the 4 week time point indicated the presence of relatively fewer viable cells compared to
the number of cells originally present at the time of implantation indicating substantial
cell death in the initial grafting process (51) . However, the seeded SIS grafts exhibited
progressively organized tissue regeneration at subsequent time points compared to
unseeded SIS (51). The feasibility of cell-seeded SIS for repairing bladder defects was
further investigated in a canine model of subtotal cystectomy (90% partial cystectomy)
with a control group which received no augmentation (63). Unlike previous studies with
smaller bladder defects, tissue regeneration was not achieved in this study with no
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statistically significant difference in bladder capacity, function, or SMC regeneration
among the three (seeded SIS, non-seeded SIS, and control) groups. This was mainly due
to the inflammation and scarring of the remaining bladder from the cystectomy and the
lack of neo-vascularization to the implanted grafts (63). These results suggest that cellseeded SIS implant may be useful for repairing minor bladder defects, but methods to
rapidly establish vascular networks into the implanted tissue would be an important
requisite for improving its applicability to repairing of larger bladder defects. The various
advantages of SIS including biocompatibility, degradability, and its ability to be used as
an “off the shelf” bladder scaffold makes it an attractive option for bladder repair.
However, there has not been an effective way to control graft shrinkage or encourage
large scale bladder regeneration. Overcoming these barriers, would pave the way for SIS
to be used as a scaffold for bladder tissue engineering.

Silk Fibroin Scaffold
Over the past decade, silk fibroin has been investigated as potential scaffold
materials for diverse tissue engineering applications such as bone, cartilage, ligament and
skin (64) mainly because of its exceptional combination of high tensile strength and
elasticity (65) Recently, using a murine model of bladder augmentation, Mauney et al.
investigated the utility of gel spun silk fibroin scaffolds in bladder tissue engineering
applications. After 70 days of implantation, the tubular shaped, non-cell seeded, silk
fibroin scaffolds showed regeneration of smooth muscle and urothelial layers along with
evidence of substantial de novo ECM deposition with no signs of scaffold degradation.
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Cystometric analyses revealed that the voided urine volume and overall capacity of the
augmented bladders were comparable to those of the non-surgical control animals after
70 days. The augmented bladder, however, exhibited a mild, acute inflammatory reaction
and high voiding frequency, which was presumably attributed to incomplete urothelial
maturation (66). Though silk fibroin has been known to elicit minimal inflammatory
response due to its presence in the human body, the absence of scaffold degradation even
after 70 days is a matter of concern. Further studies to characterize degradation of the
scaffold would help in deciding the fate of the polymer in bladder tissue engineering
studies.
Poly (lactic-co-glycolic acid) (PLGA)
Several in vivo studies have been performed to study the efficacy of cell-seeded
PLGA scaffolds toward bladder tissue engineering applications. For example, human
adipose-derived stem cells (ASC) were seeded on a PLGA scaffold designed to replicate
the tissue architecture of the native bladder and cell differentiation was examined in vitro
and in vivo in a rat model (67). Specifically, the luminal surface of the construct was
made from a thin layer of malleable and non-porous PLGA microfibers, which were
tightly woven to keep the urine from permeating the graft yet strong enough to hold solid
sutures without tearing. A thicker, 95% porous PLGA sponge was added to the outer
surface of the composite to provide a greater surface area for ASC seeding and to aid host
cell penetration and vascularization when implanted in adult female Rnu athymic rats.
Unseeded PLGA scaffolds and suture closed scaffolds were prepared identically as
controls. The authors reported that ASCs differentiated into smooth muscle cells within
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the cell-seeded bladder constructs after 12 weeks, which were evidenced by expression of
molecular markers such as α-actin, calponin, caldesmon and smooth muscle myosin
heavy chain (MHC) (67). In addition, the ASC-seeded bladder constructs maintained
viability in vivo and exhibited greater ex vivo contractility, compliance, and smooth
muscle mass compared to the control bladder constructs after 12 weeks of implantation.
However, the regenerated bladder in all the animals displayed signs of bladder calculi
(67), which must be addressed and avoided in future studies. Moreover, the results that
the acellular controls also formed a tissue structure similar to that of ASC-seeded
constructs suggest that the contribution of ASC to the regeneration of the bladder has to
be carefully evaluated. These results are highly encouraging and demonstrated the
potential of PLGA as an appropriate scaffold that support bladder regeneration and
induce ASC differentiation into SMC. However, further studies using larger animal
models are necessary to demonstrate the true efficacy of the PLGA scaffolds in bladder
tissue regeneration.

Collagen Gel Scaffolds
Collagen (especially types1 and 4) is one of the major components of the
extracellular matrix (ECM) and contains various cell adhesion domains important for
maintaining native phenotype and activity of cells (68). It is readily purified from various
animal tissue sources via enzyme treatment and salt/acid extraction; purified collagen
products have been approved by the US Food and Drug Administration (FDA) for
multiple medical applications (69). Most collagen scaffolds used in bladder tissue
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engineering are in the form of hydrogels and studies have shown cell compatibility,
normal urothelium growth, and retention of contractile phenotype of SMC in collagen
gels (70). One of the major problems associated with collagen hydrogels, however, is its
mechanical strength that is not adequate for tissue wall reconstruction. For this reason,
plastic compressed (PC) collagen gels have been proposed as a novel method to improve
the mechanical properties of neo-tissues (71). PC collagen constructs were made by a
simple and fast method and yield controllable mesoscale structures. Briefly, collagen gel
(pre-seeded with SMC and UC) was sandwiched between two nylon meshes placed on
top of a stainless steel mesh and filter paper and loaded with a 50g flat plastic block for 5
min at room temperature (Figure 1-8).

Figure 1-8: Routine assembly for plastic compression of pre-formed collagen gels.
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The compression led to the expulsion of over 95% of the water contained within
the gel and formation of a 20-40µm thick flat collagen sheet with viable cells inside.
Although PC collagen scaffolds supported cell growth for two weeks and exhibited
greater tensile properties compared to uncompressed collagen gels, the gels were not
strong enough to withstand suturing and handling in ultimate clinical use (69). It was,
thus, necessary to improve upon these limitations by combining PC collagen gels with
biodegradable synthetic meshes composed of poly (lactic acid-co-ε-caprolactone)
(PLAC) (72). PLAC was chosen as it was a slow degrading, elastic polymer and could
provide the appropriate mechanical strength. The hybrid scaffolds were prepared by
placing PLAC meshes between two layers of neutralized collagen gels, which were then
subjected to plastic compression. The scaffolds were subjected to in-vitro analysis to
determine cell phenotype, distribution, and proliferation over a period of 14 days.
Furthermore, the PC collagen-PLAC hybrid scaffolds were implanted subcutaneously in
adult Swiss nude mice for up to 24 weeks to determine their biocompatibility. The results
of the in-vitro tests demonstrated that human SMCs and UC’s embedded together in the
hybrid scaffold proliferated well on the outer surface and interior of the scaffold by 14
days. The specimens supported a maximum force of 33.62 ± 5.69 N before rupture. This
force level corresponds to a pressure of 571 cmH2O indicating that the hybrid scaffold
strong enough to withstand internal bladder pressures (40-60 cmH2O in adults during
bladder contraction) (72). The in-vivo studies provided evidence of neutrophil and
macrophage infiltration into the hybrid scaffold as early as 2 days after implantation,
which subsided after 28 days indicating a resolution of inflammation. However, a rise in
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the presence of immune cells such as macrophages and foreign body giant cells was
noted in the PC collagen-PLAC hybrid scaffolds after 24 weeks of subcutaneous
implantation. It was speculated that the degradation products of the PLAC mesh caused a
rise in inflammation reaction. The in-vivo studies also indicated near absence of SMC
and UC activity in the hybrid scaffolds after 28 days (72). Although the in-vitro results
were highly promising, the hybrid scaffolds in the current form do not seem to support
cell growth and are susceptible to inflammation in vivo. Addressing these long-term, host
response issues through strategic designing of polymer materials would certainly increase
the utility of the hybrid scaffolds in bladder tissue engineering.
Based on the results of the studies to date, future studies in bladder tissue
engineering should specifically focus on two major issues: (1) improving the strength and
compliance of the material to support the bladder’s main functions to store the urine
(while maintaining low pressure) for a considerable period of time, and to withstand
internal bladder pressures (40-60 cmH2O in adults during bladder contraction) during
voiding; and (2) maintaining the contractile phenotype of the SMC (associated with
increased compliance of the smooth muscle layer) in the scaffold so as to prevent fibrosis
(associated with synthetic phenotype).
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Chapter 2
RATIONALE AND SPECIFIC AIMS
Various diseases including congenital malformations (e.g., myelomeningocele)
and postnatal diseases (e.g., bladder cancer) of the lower urinary tract affect
approximately 400 million people worldwide (12). Current surgical treatments for these
disorders rely on the use of autologous intestinal segments and xenografts such as small
intestinal submucosa, which suffer from various complications including mechanical
mismatch and graft shrinkage (73). Atala and colleagues reported successful outcomes
implanting collagen-PGA based tissue engineered neo-bladders in both dogs and humans
(13, 46). However, Phase II clinical trials of the same approach using the autologous cellseeded collagen-PGA/PLGA scaffold for patients suffering from neuropathic bladders
demonstrated multiple adverse events such as bowel obstruction and bladder rupture,
without improving capacity or compliance (74) which resulted in discontinuation of the
study. Although the exact reason for this failure is still unknown, flaws in scaffold
mechanical properties and design as well as the use of autologous cells from the diseased
bladder may need to be reevaluated (74). For successful urinary bladder tissue
engineering, further studies are necessary. Based on the results of the studies to date, the
objective of this doctoral dissertation was to characterize various scaffold biomaterials
seeded with bladder smooth muscle cells, which would mimic the mechanical properties
of the bladder for tissue engineering applications.
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The Specific aims of the present research were as follows:
AIM 1: In vitro characterization of composite hydrogel scaffolds for application in
bladder tissue engineering
Approaches: Tetronic (BASF) 1107-acrylate (T1107-A) in combination with ECM
moieties, collagen and hyaluronic acid were tested in this application. BSMC were
encapsulated in the composite scaffolds and cell morphology, collagen production as well
as mechanical properties of the cellular hydrogels constructs were examined.
AIM 2: In vitro characterization of biodegradable elastomers for application in bladder
tissue engineering
Approach: Uni-axial and bi-axial tensile tests and pressure-volume tests of the scaffolds
were performed to quantify the ability of the scaffolds to withstand tension and pressure.
Immuno-staining of the BSMC seeded on scaffolds were also performed to confirm
cytocompatibility of the elastomers.
AIM 3: Conditioning of the BSMC seeded scaffold using a custom-made bioreactor
Approach: BSMC seeded on PCUU scaffolds were subjected to sustained tension by our
custom-made bioreactor to determine the effect of tension on BSMC.
AIM 4: Pilot in vivo study for bladder augmentation in bladder outlet obstruction (BOO)
induced rats
Approach: PCUU scaffolds will be augmented into a BOO rat bladder for a period of
three weeks to characterize cellular infiltration, bladder capacity and voiding volume.
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With the completion of these aims, we expect to advance our knowledge in the field of
bladder tissue engineering specifically related to mechanical characterization of scaffolds
and augmentation of these scaffolds in diseased bladder models.
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Chapter 3
TETRONIC®-BASED COMPOSITE HYDROGEL SCAFFOLDS SEEDED WITH
RAT-BLADDER SMOOTH MUSCLE CELLS FOR URINARY BLADDER
TISSUE ENGINEERING APPLICATIONS
Introduction
Bladder augmentation has been conventionally performed using autologous
natural tissue such as a portion of the intestine (enterocystoplasty) (28) to treat patients
who lack sufficient bladder capacity or detrusor compliance (73). However,
enterocystoplasty can generate long-term complications, including mucus production by
bowel epithelium, stone formation, malignancy and bacteriuria (4, 26). Other tissue grafts
such as skeletal muscle flaps (35) and human amniotic membrane (37) have limitations
including lithogenesis and immature smooth-muscle layer development (35, 37).
Researchers have studied other tissue engineering approaches in bladder augmentation
with cell-seeded collagen-PGA/PLGA composite scaffolds (47) small-intestine
submucosa (SIS) (38), (51, 63) and multilaminate matrices derived from silk fibroin (66).
However, these materials exhibited inadequate peak strain, (75) or extensibility (76)
when compared to native bladder tissues (50). For example, the collagen-PGA/PLGA
scaffolds that were used in human clinical studies (13, 74) would exhibit twice the
stiffness (Young’s modulus ~0.002 MPa) compared to native bladder tissue (Young’s
modulus ~0.001 MPa) (47) and hence, doesn’t allow natural distension and contraction
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required for normal bladder function. Thus, mechanical mismatch is a major obstacle in
designing a scaffold for bladder tissue engineering applications.
Hydrogels have been investigated as scaffold materials because they display low
sliding resistance against other tissues and viscoelastic mechanical properties similar to the
extracellular matrix (ECM) (52). The mechanical properties of hydrogels can be
manipulated based on the cross links formed between polymer chains via chemical bonds
and can be designed according to mechanical necessities (52). The high water absorbance
and liquid content (> 20 wt %) of hydrogels enables adequate nutrient and waste transport
to support encapsulated cells (77). Thus, synthetic and biologically-derived hydrogels are
being explored as potential scaffold material for bladder tissue engineering applications.
For example, using matrix metalloproteinase (MMP)-sensitive poly (ethylene glycol)
(PEG) hydrogels (78), Adelow and colleagues demonstrated that human mesenchymal
stem cells (MSC) seeded on these scaffolds differentiated into bladder smooth muscle-like
cells after two weeks in culture (55). However, PEG-based scaffolds in general tend to be
relatively weak for the mechanical necessities of a number of load-bearing organs
including the urinary bladder (79) and have the drawback of post-polymerization swelling.
Thus, alternative approaches are needed to improve the strength and stiffness of hydrogelbased bladder grafts.
Tetronics (BASF) are four-armed polyethylene oxide-polypropylene oxide (PEOPPO) block copolymers comprised of a hydrophobic PPO core domain surrounded by a
hydrophilic PEO shell (80). When compared to PEG hydrogels that are prepared only by
covalent crosslinking, Tetronic-based hydrogels are prepared by a combination of covalent
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and noncovalent cross-linking, leading to improved physical properties. Previously, Sefton
and colleagues characterized the semi-synthetic Tetronic T1107-collagen hydrogels
(photo-polymerization of T1107-methacrylate in collagen-containing aqueous solutions)
and demonstrated that the hydrogel scaffolds exhibited higher storage and loss moduli than
pure collagen gels (80). Although in this report human hepatoma HepG2 cells embedded
in T1107-collagen were viable, (21) synthetic hydrogels with highly cross-linked networks
tend to restrict proliferation and migration of encapsulated cells and delay matrix
production in early stages of tissue remodeling (81). To mitigate this, Kutty and colleagues
explored addition of hyaluronic acid (HA) to PEG-based hydrogels and demonstrated
improvement in spreading and cell proliferation of fibroblasts within the construct (81).
The addition of hyaluronidase inhibitors neomycin trisulfate and ascorbic acid-6-palmitate
eliminated fibroblast-spreading within HA-containing semi-IPNs, confirming the
importance of enzymatic HA degradation in creating localized imperfections leading to
fibroblast proliferation. These studies have demonstrated that combination of synthetic
moieties such as T1107-methacrylate and PEG-bis-AP with ECM components such as
collagen and HA improved overall strength and stiffness of the hydrogel construct and
could serve scaffolds for tissue engineered applications. However, little is known about the
effect of encapsulated cells on the mechanical properties of these hybrid synthetic-ECM
hydrogel scaffolds.
The objective of the present study was to characterize a composite hydrogel
scaffold as a matrix material for culture of BSMC in vitro. This is the first study to explore
the use of hydrogel blends composed of Tetronic T1107-acrylate (T1107A) in combination
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with type I collagen and HA toward applications in urinary bladder tissue engineering. We
examined cell morphology and ECM production by BSMC embedded in this composite
hydrogel system and the time-course variation in the mechanical behavior of the cellseeded composite hydrogel constructs.

Materials and Methods
Materials
Free samples of Tetronic T1107 (T1107, MW: 15 kDa, HLB: 18-23) and Irgacure
2959 were obtained from BASF corporation (USA). Acryloyl chloride, Celite 500 fine and
4-methoxyphenol, and hexanes were purchased from Sigma-Aldrich (St.Louis, MO, USA).
Toluene (HPLC grade), ethyl ether (anhydrous, BHT stabilized), hexanes (HPLC grade)
and anhydrous sodium sulfate were purchased from Fisher Scientific (NJ, USA).
Dichloromethane (HPLC grade), triethylamine (TEA), sodium bicarbonate, calcium
hydride and CDCl3 were obtained from Acros Organics (NJ, USA). Dichloromethane was
dried with calcium hydride and stored over molecular sieves (Grade 514, Type 4A). RPMI
1640 medium and trypsin-EDTA (0.05 %) were obtained from Gibco/Life Technologies
(Canada). Fetal Bovine serum (FBS) was obtained from Hyclone (Logan, UT), Collagen
type I from MP Biomedicals (Solon, OH, USA) and hyaluronic acid (HA) from SigmaAldrich (St.Louis, MO, USA). All chemicals were used as received.
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Cell culture
BSMC were isolated from the bladders of adult Sprague-Dawley rats (Female,
~12 weeks old) following our established methods (62). Prior to harvesting of the organs,
the rats were euthanized in accordance with the policies of Clemson’s Institutional
Animal Care and Use Committee based on the Animal Welfare Act. Briefly, using the
aseptic technique, the mucosal layer of the bladder was mechanically removed under a
dissection microscope, and the rest of the tissue was digested in a solution containing
RPMI 1640 medium, 0.1% collagenase (Type II, Worthington, NJ), and 0.2% trypsinEDTA to dissociate cells from the extracellular matrix. The smooth muscle cells were
collected by centrifugation of the tissue digest and then cultured in RPMI medium
supplemented with 10% FBS and 1% Pencillin-Streptomycin (P/S) under standard cellculture conditions (37 °C, humidified, 5% CO2 / 95% air). The smooth muscle phenotype
of these cells was confirmed by immunostaining with mouse monoclonal antibodies for
α-smooth muscle actin (1:500 dilution, Sigma-Aldrich, USA) and smooth muscle myosin
heavy chain (SM1(1:400 dilution) & SM2(1:500 dilution); Hybridoma Banks, University
of Iowa). Fluorescently labeled Alexa Fluor 488 was used as the secondary antibody
(Invitrogen, 1:200 dilution). The immunostaining and imaging revealed that the isolated
rat bladder SMC clearly expressed both α-smooth muscle actin and SM-MHC (SM1 and
SM2) up to six passages. Therefore, only cells up to six passages were used in these
experiments.
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Synthesis of T-1107 acrylate
T1107-acrlate (T1107A) was prepared by reaction of T1107 terminal hydroxyl
groups with acryloyl chloride (82). Briefly, T1107 (30g; 2 nmol) was dehydrated by
azeotropic distillation for 2 h with toluene, which was then removed by rotary
evaporation (Buchi Rotavapor®, Switzerland). After being cooled to room temperature,
the dried T1107 was dissolved in 270 ml dehydrated dichloromethane and mixed with
TEA (1.694 ml; 8 mmol). Acryloyl chloride (1.494 ml; 9 mmol) in 30 ml of dry
dichloromethane was added drop-wise to this mixture, and the reaction was allowed to
continue at 4◦C for 24 h. The reactant was filtered through Celite to remove TEA-HCl
salt and then concentrated by rotary evaporation to reduce the solvent to one-tenth of its
initial volume. The residue obtained was precipitated in 250 ml of cold ethyl ether and
250 ml of hexane, recovered by filtration and dried under vacuum for a few hours. The
product was redissolved in 300 ml of dichloromethane and washed with 30 ml of 10%
w/v sodium bicarbonate solution until the pH of the solution was neutral. This was
followed by water washes (30 ml each) until the pH of the water was neutral and drying
with anhydrous sodium sulfate. After the solution was concentrated by rotary
evaporation, the residue was precipitated and washed three times with cold ethyl ether
(−20 °C). The final product was recovered by filtration, dried for 48 h in a vacuum
desiccator and stored at 4°C until use (82). The NMR (Bruker Avance III 300, USA)
spectra obtained on the final product was used to determine its acrylation efficiency.
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Preparation of composite hydrogel
The T1107A (117.5 mg/ml) powder was added to collagen type I solution (6
mg/ml in 0.02 N acetic acid) and mixed overnight at 4 °C. The collagen-T1107A
solution (319 µl) and photo-initiator Irgacure 2959 (I-2959; 7.5 µl, 1:10 dilution in
ethanol) were incubated at 4ºC for 30 min with periodic vortexing. The centrifuge tubes
containing the hydrogel solution were then brought to room temperature inside the
biosafety cabinet; subsequently, hyaluronic acid (HA) (MW=1.5-1.8 MDa; 75-150 µl;
1:100 dilution in H2O) was added to this solution using a 1000 µl pipette. BSMC (4x
106/ml) in 3X RPMI +10% FBS solution were then mixed into the solution to form the
final hydrogel solution (0.75mL), composed of 5% T1107A, 0.25% collagen type I, 0.10.2% HA, 0.1% I-2959 and ~3x 106 cells. The total volume was balanced using 3X
RPMI + 10% FBS solution for different concentrations of HA, and the BSMC were
omitted in acellular hydrogels. The gel specimens were cast in custom-made Teflon
molds (3cmx1cmx0.5cm) with biovyon (Porvair plc, Norfolk, UK) wafers on the ends as
anchors (62) and polymerized under UV light for 12 min. The SMC-seeded composite
hydrogel constructs were cultured in RPMI medium supplemented with 10% FBS and
1% penicillin-streptomycin for up to14 days.

Quantification of mass swelling ratio of composite hydrogel
Acellular hydrogel specimens were equilibrated in PBS for 24 h to remove
unpolymerized monomers and lyophilized. After dry weights (wd) were recorded, the
specimens were soaked in distilled water and allowed to swell for 24 h. Subsequently the
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wet weights (ws) were recorded, and mass swelling ratio, q, was calculated as the ratio of
wet to dry weight (ws / wd).

Examination of BSMC viability and morphology
BSMC viability inside the composite hydrogels was qualitatively determined with
a live/dead viability/cytotoxicity kit (molecular probes, NY, USA). After 4, 7 and 14 days
in culture, the composite hydrogels were incubated with 2µM Calcein-AM to stain the
living cells and 4µM Ethidium homodimer-1 to stain the dead cells. After 30 min, the
constructs were visualized using a laser confocal microscopy (C1Si Confocal; Nikon Ti
Eclipse).
To qualitatively determine cell morphology, the BSMC encapsulated in the
hydrogel were fixed in paraformaldehyde (1:50 dilution in PBS, P6148, Sigma) at room
temperature for 15 min, and the excess aldehyde in the constructs was quenched with
0.1M glycine (T9284, Sigma) for 5 min at the end of the prescribed time periods. The
cells were permeabilized with 0.1% triton-X 100 (T9284, Sigma) for 1 min and incubated
with rhodamine-phalloidin (1:100 dilution in PBS, R415, Molecular Probes/invitrogen)
for 15 min. This was followed by nuclear staining with DAPI (1:100 dilution, D-1306,
Molecular probes, Eugene, OR) for 5 min. The hydrogels were then subjected to
triplicate PBS washes for 5 min, and the specimens were imaged using laser confocal
microscopy (C1Si Confocal; Nikon Ti Eclipse).
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Mechanical characterization of composite hydrogel
The mechanical characterization of the composite hydrogels was performed by
uniaxial tensile testing using MTS Synergie 100 to quantify peak stress, elastic modulus
and peak stretch of the samples. The dog bone-shape hydrogel constructs were subjected
to tension under hydrated conditions (PBS at 37ºC) at a rate of 5mm/min until rupture.
Average Lagrangian peak stress values were calculated from the load applied to the
specimens over continuous time-points divided by the original cross-sectional area of the
hydrogel. The stress-stretch relationship was analyzed where stress (τ) was plotted
against stretch (λ) (where λ is the stretch ratio of deformed to reference lengths). The
elastic modulus (kPa) of the hydrogels was calculated from the linear regions of their
respective stress-strain curves. Peak strain was also calculated.

Quantification of collagen synthesis by BSMC
After 7 and 14 days of culture, hydroxyproline assay was performed according to
the published method to quantify the collagen synthesized by BSMC (hydroxyproline
represents 12% of collagen (w/w)) (83). Acellular hydrogel samples were used as
control. Briefly, all hydrogel samples were flash frozen in liquid nitrogen and
lyophilized using a freeze dry system (Freezone 4.5, Labconco, USA). The lyophilized
samples were then hydrolyzed in 4N NaOH at 120 ºC for 4 hours and neutralized with
citric acid (1.4N). Series concentrations (0-50%) of hydroxyproline (100µg/ml) dilutions
were prepared as standards. Each of the samples and standards was mixed with 1 ml of
chloramine-T and incubated at room temperature for 20 min. This was followed by
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addition of p-dimethylaminobenzaldehyde (PDMAB) and additional incubation at 65°C
for 15 min. The light absorbance of samples was measured at λ=550 nm in triplicate
using a universal microplate spectrophotometer (µQuant, Biotek Instruments Inc., USA).

Statistical analysis
All numerical data were analyzed using the single-factor Analysis of Variance
(ANOVA), followed by a post-hoc test when statistical significance was detected. All
statistical analyses were performed using JMP ANOVA statistical software package
(SAS, NC, USA). Four samples were used for uniaxial mechanical testing and three
samples were used in the hydroxyproline assay.

Results
Synthesis of T-1107 acrylate
Schematic representation of T1107A synthesis is shown in Figure 3-1. The
percent acrylation efficiency was calculated based on the ratio of the integrals of the PEG
backbone (δ=3.5-3.7) and acrylic peaks (δ=6.15-6.4) (Figure 3-2) as previously shown in
studies done by Cho et al. (84). A yield of 22.5 g of T1107A was obtained from the
original 30g of T1107 used in the synthesis and T1107A having more than 85%
acrylation efficiency was used in the experiments. Efficient removal of unreacted
acryloyl chloride was confirmed by the ratio of acrylate to activated PEG terminal
(δ=4.3) methylene peaks, which closely approximated the theoretical value, 3:2.
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Figure 3-1: Schematic representation of synthesis of T1107A.The formation of
acrylate groups on all four arms of T1107, a block copolymer of (a) Polyethylene oxide
(PEO) and (b) polypropylene oxide (PPO), is described.
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Figure 3-2: Representative 1H-NMR spectrum of acrylated T1107. Analysis of the
NMR data based on the integrals of the PEG backbone (δ=3.5-3.7) and acrylic peaks
(δ=6.15-6.4). The integrals include δ = 1.1 (a, PPO CH3), 3.4 (a, PPO CH), 3.54 (a, PPO
CH2), 3.65 (a,PEO CH2), 4.32 (-CCH2OC (=O)-), 5.8 and 6.4 (2H, acrylic –CH2),
6.15 (1H, acrylic –CH) ppm.

Mass swelling ratio and mechanical characterization of composite hydrogel scaffold
The ratios of swollen mass to dry mass of acellular composite hydrogel specimens
(Figure 3-3) were similar for the three different concentrations of HA (0.1, 0.15 and
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0.2%) used in the hydrogels (Figure 3-4A). In contrast, the results of tensile testing
indicated that higher the concentration of HA, greater the elastic modulus (defined as the
slope of the linear region of the stress/stretch curve) of the composite hydrogels (Figure
3-4B). The formulations containing 0.15 and 0.20% HA exhibited significantly (P<0.01)
greater elastic modulus (stiffness) than the specimens with 0.10% HA content (Figure 34B). Based on this result, we incorporated 0.2% HA in our composite hydrogels for the
rest of our study.

Figure 3-3: Representative image of the acellular composite hydrogel. The composite
hydrogel was obtained by subjecting the gel composition to UV radiation for 12 minutes
between BioVYON wafers which assist as grips during uniaxial tensile testing.
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Figure 3-4: Effect of HA content on the mass swelling ratio and elastic modulus of
the composite acellular hydrogels. While swelling ratio (A) was unaffected, the elastic
modulus (B) increased significantly as concentration of HA in the composite hydrogels
increased. Values are mean ± SEM, * p<0.01, n=3 per group.

BSMC Cell Viability and Morphology
The live/dead study indicated the presence of viable cells in the scaffold at a
magnification of 100X after 4, 7 and 14 days of culture (Figure 3-5). The Rhodaminephalloidin staining and confocal imaging revealed distribution of BSMC up to a depth of
1.13 mm of the construct, which after 14 days in culture, revealed an increased
distribution for a depth of 1.26 mm along with increased BSMC migration towards the
surface of the hydrogel scaffolds (Figure 3-6A and 3-6B). When the constructs were
viewed at the 600X magnification at the 14 day time-point, the individual BSMC
demonstrated a spread cell morphology (Figure 3-6C).
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Figure 3-5: Live/Dead staining of BSMC in the composite hydrogel. High viability of
BSMC was confirmed by the presence of live (green) cells and the absence of dead (red)
cells in the scaffold after 4 (A), 7 (B) and 14 (C) days of cell seeding. In addition, BSMC
exhibited spread cell morphology at day 14 (C) (Magnification=100X).
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Figure 3-6: Confocal imaging of BSMC in the composite hydrogels. The results
demonstrate BSMC are well distributed at day 4 (A: magnification = 40X), and increased
cell migration towards the surface at day 14 (B: magnification = 40X). The spread
individual bladder smooth muscle cells are also seen at the 14-day culture period (C:
magnification = 600x).
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Effects of cell-seeding on mechanical properties of composite hydrogel
When compared to acellular gels (Peak Stress: 4.1 ±1.2 kPa, Elastic modulus
(stiffness): 11.8 ±1.1 kPa, Peak Stretch: 1.21±1.23) hydrogels seeded with BSMC (4 X
106 cells /mL) exhibited greater values for peak stress, peak stretch, and elastic modulus
(Figure 3-7). Among the BSMC-seeded hydrogels, specimens cultured for 14 days
exhibited significantly (P<0.05) greater values of peak stress (11.6± 2.2 kPa) and elastic
modulus (42.7 ± 4.0 kPa) compared to specimens cultured for 7 days (Peak stress:
5.2±0.6 kPa, Elastic modulus: 19.3±2.8 kPa). When compared to cell-seeded hydrogel
specimens cultured 7 days (1.23 ± 0.04), specimens cultured 14 days (1.39±0.12)
exhibited peak stretch values with a strong trend of higher value; this was not statistically
different due to large variability(Figure 3-7B).

Figure 3-7: Mechanical properties of the composite cellular hydrogels. Specimens
were subjected to uniaxial tension at the rate of 5mm/min until failure and average peak
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stress (A), peak stretch (B) and elastic modulus (C) were calculated from the stressstretch relationship (D) of composite cellular hydrogels at the 7 and 14 day time point.
The lines across the bar graphs represent the corresponding values for acellular composite
hydrogels (0.2% HA). Values are mean ± SEM; analyzed by ANOVA, *p<0.05,
**p<0.01, n=4.

Hydroxyproline assay
The results of the hydroxyproline assay indicated that compared to acellular
samples (35.1± 3.1 µg collagen/mg sample mass), the 7-day (48.5 ± 9.6 µg collagen/mg
sample mass) and 14-day cellular constructs (61.7 ± 5.9 µg collagen/mg sample mass)
contained significantly (p < 0.05) greater amounts of collagen (Figure 3-8)

Figure 3-8: Collagen concentration in the composite hydrogels. Results of
hydroxyproline assay revealed that cellular specimens contained significantly greater
amounts of collagen after 7 and 14 days of culture compared to the acellular specimens.
Values are mean ± SEM; *p<0.01, n=3.
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Discussion
The long-term goal of the present study is to develop a functional 3D tissue
construct for bladder augmentation. In pursuit of this goal, we prepared a composite
hydrogel using a blend of Tetronic T1107A, type I collagen, and HA cross-linked to form
a semi-IPN scaffold for encapsulation of BSMC. First, to evaluate the impact of HA
inclusion on mass swelling ratio and elastic modulus (stiffness) of our composite
hydrogel, different concentrations of HA (0.1%, 0.15%, 0.20%) were mixed into the
acellular hydrogel constructs. Results show that while the mass swelling ratios of
hydrogels with different concentration of HA were nearly identical, the elastic moduli
increased with increasing concentration of HA (Figure 3-4). These results are in
agreement with the report by Kutty et al., which demonstrated that in PEG-bis-AP/HA
semi-IPNs, increasing concentration of HA from 0.06% to 0.18% caused a minimal
increase in volumetric swelling ratio and a significant increase in elastic modulus relative
to controls without HA (81). The lack of any change in the mass swelling ratio indicates
that the inclusion of HA in our composite scaffold did not affect the density of the
construct’s crosslinks and consequently, did not affect swelling. These results are in
contrast with a previous study, which demonstrated that in collagen-HA semiinterpenetrating network hydrogels, inclusion of increasing concentrations of HA led to a
corresponding decrease in the swelling ratio (85). This was because the HA chains in the
collagen-HA semi-interpenetrating network hydrogels were cross-linked into the
composition, causing stiffer gels (86). In the present study, the HA molecules were not
cross-linked, and they merely entangled with the main Tetronic network inside the
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composite hydrogels. Thus, increasing HA weight percentage did not cause increased
crosslinking and decreased swelling. However, HA solid content, due to its high
molecular weight relative to collagen (81), molecularly reinforced the hydrogel (86) and
had a significant impact on elastic modulus (stiffness) of the composite scaffold (Figure
4). Previous studies have shown that the elastic modulus of alginate gels is affected by
the molecular weight of polysaccharides encapsulated in it (87). HA, one of the longest
types of glycosaminoglycans (GAG), led to increased elastic modulus (stiffness) in the
composite hydrogel with increasing concentration. This was demonstrated by Kim et al.,
who showed that higher weight percentage of HA led to increased elastic modulus in
MMP-sensitive HA-based hydrogels (88).
In the present study, the BSMC encapsulated in composite hydrogel displayed
high cell viability at various time points (Figure 3-5). Moreover, the confocal imaging
demonstrated that distribution of BSMC was visible in the scaffold (Figure 3-6). These
results are in agreement with previous studies that during a similar culture period, smooth
muscle cells seeded in collagen-based hydrogels tended to migrate towards the surface of
the constructs (69, 89). The increased BSMC distribution may be due to facilitation of
cell spreading and migration by the degradation of HA and localized increases in mesh
size of the scaffold, as previously reported with fibroblasts encapsulated in HAcontaining PEG-based semi-IPN hydrogels (81). Though BSMC at 4 and 7 days
exhibited the round morphology of the synthetic phenotype of smooth muscle cells
(Figure 3-5A and 3-5B), the BSMC at the 14day time-point exhibited a more spread
morphology (Figure 3-5C and 3-6C).
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In mechanical testing, the hydrogel scaffolds increased in strength and elastic
modulus (stiffness) when seeded with BSMC and cultured for up to 14 days. Compared
to the acellular hydrogels, the mechanical properties (peak stress, peak strain and elastic
modulus) of the cellular hydrogels were significantly greater. The average peak stress and
elastic modulus of the BSMC-seeded composite hydrogels were significantly (p < 0.05)
higher 14 days after cell seeding than specimens tested 7 days after BSMC seeding. We
hypothesized that the increase in strength and elastic modulus (stiffness) of the cellular
constructs was due to de novo ECM synthesis by BSMC, and we quantified the amount
of collagen within the cell-seeded composite hydrogel specimens using hydroxyproline
assay (90). Collagen (especially types 1 and 3) is the major protein of the urinary bladder
ECM and contains various cell-adhesion domains important for maintaining native
phenotype and cellular activity (91). Since the 7-day and 14-day cellular constructs
contained significantly (p < 0.05) greater amounts of collagen per specimen mass than the
acellular composite hydrogel scaffolds (Figure 3-5), we concluded that BSMC deposited
the newly synthesized collagen, which led to the increase in strength and stiffness of the
gel constructs (Figure 3-4). Although the increased collagen content suggested correlative
increases in mechanical strength, the ultimate tensile stress of the BSMC-seeded
composite hydrogels in the present study (11.6 ± 2.2 kPa) did not display the level
achieved in other studies (89) or an estimated peak physiological stress of the native
bladder (~100 kPa) (92). This may be because the two-week end-point used in the
present study was too short (89) or chemical stimulation was needed to support
crosslinking of newly synthesized collagen fibrils that contributes to the stiffening of the
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overall construct (93). For example, Berglund et al. reported that the ultimate tensile
stress of endothelial cell-seeded collagen hybrid scaffolds was more than 100kPa at the
end of 23 days (94). Tranquillo and colleagues demonstrated that addition of 1or 5 ng/ml
of TGF-β1 and 2µg/ml of insulin led to a seven-fold increase in collagen concentration
and cross-linking with a three-fold increase in ultimate tensile strength in fibrin gel-based
constructs seeded with neonatal vascular smooth muscle cells (95). Thus, to promote
cross-linking of the newly synthesized collagen it may be necessary to culture the
composite hydrogels for longer time periods of 3-5 weeks and/or in the presence of
soluble chemical compounds.
In summary, mechanical mismatch has been a major obstacle in designing a
scaffold for bladder tissue engineering applications. The composite hydrogel system in
our current study provided a viable environment for bladder smooth muscle cells to
survive and reconstruct the scaffold, thereby improving the construct’s overall strength
and stiffness. Culturing the construct for longer time periods after BSMC seeding and
addition of growth factors to the composite hydrogel system would further aid in
accurately mimicking the mechanical properties of the bladder wall.
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Chapter 4
IN VITRO CHARACTERIZATION OF BIODEGRADABLE ELASTOMERS FOR
APPLICATION IN BLADDER TISSUE ENGINEERING
Introduction
In the previous chapter, we discussed that the mechanical strength and stiffness of
the composite hydrogels after 14 days of BSMC seeding could not mimic the mechanics
of the bladder wall and hence, the present study explored the use of biodegradable
elastomers, namely, polyglycerol sebacate –polycaprolactone (PGS-PCL), poly (etherurethane) urea (PEUU), and poly (carbonate-urethane) urea (PCUU) as scaffold materials
for urinary bladder tissue engineering since these materials have previously been shown
to exhibit high extensibility and biocompatibility (96, 97). For example, Sant and
colleagues demonstrated that, compared to electrospun PCL-only (mesh) scaffolds,
electrospun (ES) fibrous PGS-PCL scaffolds supported greater cell attachment and
proliferation of human umbilical vein endothelial cells (HUVECs) and mitral valve
interstitial cells (MVICs) (98, 99). In separate studies, Wagner et al. demonstrated that
ES-PEUU scaffolds simulated the anisotropic mechanical response of vascular tissues
(100, 101) and promoted smooth muscle neo-tissue formation in rats with sub-acute
myocardial infraction (102). Studies on the PCUU scaffold showed that though it
degraded slower than PEUU (when implanted subcutaneously in rats at the end of 8
weeks), it also promoted native smooth muscle infiltration and growth similar to PEUU
(97). In addition to cytocompatibility, PGS-PCL, PEUU and PCUU exhibited high tensile
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strength (10-35 MPa) (97) and elongation (400-800%) (97, 103), which are ideal for
applications toward the bladder that demonstrate a peak stress (~ 1.6 MPa) and
elongation of 150-350% depending on regional variations when subjected to uniaxial
tension (7). Therefore, the present study focused on characterization of the mechanical
behavior and the in vitro cytocompatibility of these biodegradable elastomers for urinary
bladder tissue engineering applications.

Materials and methods
Materials
All elastomeric scaffolds were kindly donated by collaborators who prepared
them using conventional electrospinning methods with conditions described in previous
reports (96, 101). The PGS-PCL scaffolds (Figure 4-1A) were fabricated in the laboratory
of Dr. Ali Khademhosseini (Wyss Institute for Biologically Inspired Engineering,
Harvard-MIT). Briefly, the PGS and PCL polymers (33 wt. %) were dissolved in a
mixture of ethanol and anhydrous chloroform so that the PGS: PCL weight ratio was kept
constant at 2:1. Electrospinning was carried out at 12.5 kV using a 21G blunt needle and
at a flow rate of 2ml/hr for 30 min. The distance between the needle and the collector
were kept constant at 18 cm (96). For easy removal of the fibers non-adhesive tape was
attached to an aluminum plate to collect them. Scaffolds were stored in a desiccator until
further use (96). PEUU (Figure 4-1B) and wet PCUU (Figure 4-1C) scaffolds were
fabricated in the laboratory of Dr. William Wagner (McGowan Institute of Regenerative
Medicine, University of Pittsburgh). Briefly, PCUU was dissolved in HFIP under
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mechanical stirring at either 5 or 12 wt%. The PCUU/PEUU solution and cell culture
media (composed of DMEM media supplemented with 10% fetal bovine serum (FBS)
and 5% penicillin-streptomycin) was fed at ~0.98-1.2 ml/hour (dependent on ambient
relative humidity) using two different syringe pumps (Harvard Apparatus PhD) located at
17 cm and 4.5 cm respectively from the target (mandrel). High voltage generators
(Gamma High Voltage Research) were utilized to charge the PCUU/PEUU solution at 12
kV, cell culture medium at 9kV and their target at -7kV. The electrospinning was
performed at a rotational speed of ~200 rpm, with a 5cm motor translation pattern, which
meant the mandrel translated back and forth at a distance of 5cm, while maintaining
minimal scaffold media wetting during fabrication. The approximate fabrication time was
about two hours and the PEUU/PCUU scaffold was kept overnight in UV for sterilization
before use. There were two versions of PCUU which were fabricated; a normal version
and a slightly more compliant version (higher amount of media is added while
fabrication).

A

B
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Figure 4-1: Representative Images of PGS-PCL (A), PEUU (B) and PCUU (C).The
PCUU scaffold(wet) is stored in cell culture media composed of DMEM supplemented
with 10% FBS , 10% horse serum and 5% penicillin/streptomycin.

Uniaxial mechanical testing of elastomeric scaffolds
The mechanical testing specimens were prepared according to the ASTM
standards D3039/D3039D and subjected to uniaxial tensile loads under hydrated
conditions (PBS at 37ºC) at a rate of 18mm/min until rupture (50) using MTS synergie
100. The mechanical behaviors of these materials were analyzed by plotting the
calculated values of tension (N/mm) against stretch ratio λ (ratio of deformed to reference
lengths) and by comparing the maximum tensions and stretch ratios at failure. Since the
thickness of the elastomeric scaffolds (0.1-0.2 mm) was negligible compared to its length
and width, tension was quantified instead of stress. As a reference, the physiological peak
tension of the bladder in the human body was estimated. Using the Law of Laplace, we
calculated for membrane tension in the bladder (MT) where MT=p*R/2 where p is the
internal pressure and R is the radius of the bladder. Stress is then computed by
T=MT/thickness. In these equations, the internal radius of the normal bladder (6 mm) , the
maximum thickness (0.4 mm), and the peak pressure (75 cmH2O or 7.34 kPa) was based
on previous studies and measurements(73, 104). These computations lead us to believe
that native urinary bladders in vivo undergo a peak physiological tension of
approximately 100 kPa.
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Biaxial mechanical testing of elastomeric scaffolds
PCUU specimens approximately 6mm X 6mm in size were subjected to biaxial
mechanical testing using the CellScale BioTester (Waterloo, Canada). The BioTester was
fitted with 2.5N load cells and BioRakesTM with 1.0 mm tine spacing. The specimens
were loaded with an initial grip separation of 4.8 mm. After mounting, the grips were
moved to 5.0 mm before the start of the test in order to provide a small amount of
preload. The intended procedure was to test each specimen with increasing equibiaxial
strains until failure i.e. 20% in 20 sec (5mm to 6mm; λ= 1.2), 40% in 40 sec (5mm to
7mm; λ=1.4), 60% in 60 sec (5mm to 8mm; λ=1.6), and 75% in 75 sec (5mm to 8.75mm;
λ= 1.75). The mechanical behaviors of these materials were analyzed by plotting the
calculated values of tension (N/mm) and stress (kPa) at different strain rates. We also
computed the areal strain (= λXλY-1) under 100 kPa equibiaxial stress, where λX and λY
represent the stretch along the X and Y axes, respectively. The areal strain represents the
change in area between the reference and deformed states under planar biaxial loading.

SEM imaging of PCUU scaffolds
Rectangular PCUU specimens (thickness 0.11 mm) were created according to the
ASTM standards D3039/D3039D with the dimensions 10 X 1 mm. These scaffolds were
affixed to thin aluminum sheets (gauge -0.0084, Amerimax, USA,) under stretched states
at 1.25, 1.5, and 1.75. These samples were then imaged using SU 6600 scanning electron
microscope (Hitachi). The % porosity was determined semi-quantitatively using ImageJ
(NIH, USA).
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BSMC seeding on elastomeric scaffolds
The PCUU scaffolds (5 mm × 5 mm) were sterilized by soaking in 70 % ethanol
for at least 1 h and then washed thoroughly with sterile Dulbecco’s phosphate buffered
saline (DPBS) before cell seeding. The scaffolds are then soaked overnight in sterile
BSMC culture media composed of RPMI supplemented with 10% FBS and 1%
antibiotic/antimycotic. The culture media were removed just before cell seeding. The
BSMC were suspended in 20-25 µl of BSMC culture media at a final concentration of ~1
× 105 cells/scaffold and seeded evenly at 4-5 places on each scaffold (the scaffolds were
neither too wet or too dry while seeding the cells). The cells were allowed to attach to
scaffolds for 1-1.5 h before flooding the culture plate with additional medium. After
incubation under standard cell culture conditions (humidified, 37 °C, 5% CO2 / 95% air)
overnight, the cell-seeded scaffolds were transferred to new well plates with fresh media
to separate them from the cells attached to the bottom of PDMS wells. BSMC with six
passages or less were used in all experiments.

Characterization of BSMC viability and morphology
BSMC viability on the PCUU scaffold was determined with LIVE/DEAD assay kit
following the manufacturer’s instructions (Molecular Probes, NY, USA). After 7 days in
culture, the PCUU scaffolds were rinsed in sterile PBS following removal of media. The
scaffolds were then incubated with 2µM Calcein-AM to stain the living cells and 4µM
Ethidium homodimer-1 to stain the dead cells. After 30 min, the constructs were
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visualized using a laser confocal microscopy (C1Si Confocal; Nikon Ti Eclipse). The %
live cells was determined quantitatively using ImageJ (NIH, USA).
To determine cell morphology, the actin filaments of BSMC seeded on the PCUU
scaffolds were stained with rhodamine-phalloidin after seven days in culture. Briefly,
cells were fixed in paraformaldehyde (1:50 dilution in PBS, P6148, Sigma) at room
temperature for 15 min, and the excess aldehyde in the constructs was quenched with
0.1M glycine (T9284, Sigma) for 5 min. The cells were permeabilized with 0.1% tritonX 100 (T9284, Sigma) for 1 min and incubated with rhodamine-phalloidin (1:100
dilution in PBS, R415, Molecular Probes/invitrogen) for 15 min. This was followed by
nuclear staining with DAPI (1:100 dilution, D-1306, Molecular probes, Eugene, OR).
The PCUU scaffolds were then subjected to triplicate PBS washes for 5 min, and the
specimens were imaged using laser confocal microscopy (C1Si Confocal; Nikon Ti
Eclipse).

Characterization of BSMC marker expression
The smooth muscle phenotype of BSMC on the PCUU scaffolds was examined
by immuno-staining for α-smooth muscle actin and smooth muscle myosin heavy chain
(SM1 & SM2) after 7 days of culture. Briefly, the cells were fixed for 20 min and then
blocked using a solution composed of 2% bovine serum albumin, 3% goat serum,
prepared in PBS. After triplicate washes with PBS, the specimens were incubated with
primary anti-bodies for α-actin (1:500 dilution, Sigma-Aldrich, USA) and smooth muscle
myosin heavy chain (SM1(1:400 dilution) & SM2(1:500 dilution); Hybridoma Banks,
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University of Iowa ) followed by incubation at 4ºC overnight. The cell-seeded PCUU
scaffolds were then incubated with the secondary antibody Alexa-fluor 488 Anti-Mouse
IgG (H+L) overnight, followed by nuclear staining with DAPI for 5 minutes. The cells
were then imaged using laser confocal microscopy (C1Si Confocal; Nikon Ti Eclipse).

Pressure testing of PCUU scaffolds
Rat bladders were obtained frozen from Pel-Freeze biologicals (Rogers, Arizona)
and were thawed overnight at 4o C before use. A small (~2.0 mm diameter) defect was
created using a 18G needle (BD Precision Glide, NJ,USA) on the dome of each bladder
(~10.5 mm X 5.4 mm) on top of a half severed 100 µl pipette tip (VWR, PA, USA)
(Figure 4-2) and an acellular PCUU patch was sutured using nylon 9-0 sutures to cover
the puncture. The augmented bladder specimens were inflated with saline (with color
added using Coomassie blue for visual confirmation of leaks) using the Harvard pump
(Harvard Apparatus, Holliston, MA) at a flow rate of 0.1 ml/min until failure in the saline
bath at 37 °C. Changes in pressure during testing were recorded via a pressure transducer
and our custom LabVIEW program. Intact rat bladders with no defects were used as the
control.
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Figure 4-2: Image describing punctured PCUU on top of severed pipette tip. The
arrow denotes the puncture on the rat bladder where the PCUU will be sutured. The
severed pipette tip is held upright using pins on a PDMS bottom petri dish.

Figure 4-3: Image describing the ex vivo pressure device. The syringe pump injects
colored saline into the PCUU sutured bladder till the patch leaks. The pressure inside the
bladder is monitored by the pressure transducer and LabVIEW program.
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Results
Uniaxial mechanical testing of elastomeric scaffolds
The uniaxial tensile testing of the PGS-PCL scaffolds in the present study
revealed that although the maximum stretch was 2.15 ± 0.28, the maximum tension at
failure was on average 0.072 ± 0.005 N/mm (Figure 3). The uniaxial testing of the PEUU
revealed that a maximum tension and stretch ratio at failure were 1.75 ± 0.68 N/mm and
2.47 ± 0.52, respectively (Figure 4- 3C). In contrast, the uniaxial testing of the PCUU
scaffolds revealed that not only the maximum tension (0.43±0.029 N/mm) and stretch
(2.43± 0.26), but also the overall tension-stretch curve (Figure 4-3) were similar to those
of the native bladder reported in the literature (50).
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Figure 4-4: Mechanical properties of biodegradable elastomers. Specimens were
subjected to uniaxial tension at the rate of 18 mm/min until failure and average peak
tension (A), peak stretch (B) were calculated from the tension-stretch relationship (C) of
viscoelastic elastomer scaffolds. The parallel lines across (C) represent the corresponding
values for peak physiological tension to which the bladder is subjected in the body
varying on thickness (2-4 mm). Values are mean ± SEM; analyzed by ANOVA, *p<0.01,
**p<0.05, n=4

Biaxial testing of elastomeric scaffolds
The results indicated different tension-stretch curves for X and Y axes under
equibiaxial strains demonstrating anisotropic mechanical behavior of the PCUU scaffolds
(normal (A) and compliant (B)) at all the different strain levels. The normal variants of
PCUU required nearly twice the tension to attain the desired stretch values (1.2, 1.4, 1.6
and 1.75) when compared to the compliant variant of PCUU (Figure 4-5). Both samples
failed at 75% strain. At a stress of 100 kPa, the areal strain of the PCUU scaffolds were
estimated to be 0.13 for sample A and 0.21 for sample B respectively (Figure 4-6).
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b
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Figure 4-5: Biaxial mechanical testing of PCUU. The stress(a,b) and tension(c,d)
values of normal (n=1) and compliant (n=1) PCUU respectively at various stretch
values.The Hysteresis curves depicting normal (e)(n=1) and compliant (f) (n=1) samples
of PCUU indicate non-linear viscoelastic behavior at 20 % strain, 40 % strain, 60% strain
and 75% strain.
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Figure 4-6: Areal Strain of the PCUU samples A (normal) (n=1) and B (compliant)
(n=1) at 100 kPa. The compliant version of PCUU was nearly twice as complaint as the
normal version of PCUU.

SEM imaging of PCUU scaffolds
The results of the SEM imaging showed that the PCUU scaffolds were porous and
the fiber orientation was influenced by the direction and intensity of stretch. The increase
in stretch from 0% to 25% led to increase in porosity from 37.6 ± 3.9 % (n=3) to 54.9 ±
1.7% (n=3). The porosity % at 75% stretch was slightly higher at 57.1± 2.8% (n=3)
(Figure 4-11).

A
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Figure 4-7: SEM images of PCUU at 1000X. PCUU specimen at 0% stretch (A),
25% stretch (B) and at 75% stretch (C). The PCUU fibers align depending on the
intensity and direction of stretch (indicated by red arrow) and the % porosity increased
nearly 70% from 0% stretch to 25% stretch.

Examination of BSMC viability and morphology on the PCUU scaffolds
The LIVE/DEAD staining of BSMC showed high viability (90.11%) on the
PCUU scaffold (Figure 4-7A). Rhodamine-phalloidin and DAPI staining of BSMC
demonstrated elongated cell morphology throughout the PCUU surface (Figure 4-7B).
The smooth muscle phenotype of BSMC cultured on PCUU scaffolds for 7 days was
confirmed by positive staining for uniform expression of α-actin (SMC marker) and SM1
and SM2 (Smooth muscle myosin heavy chain markers) (Figure 8).

A

B

Figure 4-8: Live/dead (A) and Rhodamine –Phalloidin (B) staining of BSMC on
PCUU scaffolds at 100X magnification after a 7 day culture-period. High viability of
BSMC was confirmed by the presence of 90.11% live (green) cells among the total cells
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in the scaffold (A) using imageJ. The Rhodamine-Phalloidin and DAPI results
demonstrate F-actin expression in the well distributed and elongated, spindle-like bladder
smooth muscle cells (B).

A

B

C

Figure 4-9: Immuno-staining of BSMC on the PCUU scaffold with antibodies for αactin (A), SM1 (B) and SM2(C) after the 7 day time-point. The Results indicate
contractile smooth muscle cell morphology (A) and expression (B & C).

Pressure-volume testing of PCUU scaffolds
The results of the pressure –volume experiment provided evidence that bladders
patched with PCUU scaffolds withstood pressure up to 60 cm H2O (Figure 4-9) after
which the defects caused by suturing enlarged leading to leakage of colored saline from
the bladder. The control bladders could withstand pressure more than 100cm H2O after
which leakage of saline begins from the bladder at the region of connection with the
syringe pump. The pressure volume curve indicted reduction in capacity (also seen in
Figure 4-10) and reduced toe region in the sutured bladders compared to the control
bladders.
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Figure 4-10: Comparison of the pressure-volume relationship of PCUU sutured
bladders (n=1) versus native bladders (n=1). The PCUU sutured bladder withstood
pressure up to 60 cm H2O

Figure 4-11: Rat bladders at 40 cm H20 with PCUU patch (left) and without
PCUU patch (right). Arrow indicates the PCUU patch (~20% the size of the bladder)
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Discussion
Previous studies demonstrated that PGS-PCL based scaffolds designed for
vascular tissue engineering applications supported cell proliferation and ECM production
of human umbilical cord vein endothelial cells and mitral valve interstitial cells (98, 99).
Thus, we hypothesized that these scaffolds that are fabricated by combining blends of
non-acrylated PGS pre-polymer with biodegradable poly (ɛ-caprolactone) (PCL) (both
approved by FDA) (98) may provide a suitable milieu for bladder tissue engineering. The
uniaxial tensile testing of the PGS-PCL scaffolds in the present study revealed that the
maximum tension at failure was on average 0.079 N/mm. This was significantly lower
than the maximum tension for the normal human bladder 0.2-0.4 N/mm (50) and hence,
is unsuitable for bladder tissue engineering purposes due to this mechanical mismatch.
PEUU scaffolds have been used in Lewis rats as patches (1) to promote remodeling and
improve function of subacute myocardial infracts, (2) to replace a surgical defect in right
ventricles , (3) abdominal aortic wall replacement and have demonstrated smooth muscle
tissue regeneration, cellular integration, mechanical reinforcement and minimal
inflammation (105-108). Similarly, PCUU scaffolds have been used in vivo studies as
patches in lewis rats with myocardial infraction and have prevented further deterioration
and improved neovascularization and elastin levels. The uniaxial tensile testing results in
the present study demonstrated that PEUU scaffolds displayed high stiffness under low
forces, unlike the bladder tissue which exhibits a considerable toe region (large
deformation under low stress) in its stress-strain curve (50).In contrast, PCUU scaffolds
exhibited a non-linear behavior, typical of bladder tissue, displaying relatively high
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compliance at low forces and high strength to withstand physiological bladder pressures
(92). Based on these results, subsequent experiments focused on characterization of
PCUU scaffolds.
Although uniaxial tensile testing can provide insightful data, it is not
representative of physiological loading conditions in the urinary bladder, where loading
occurs in all three dimensions. Since the urinary bladder can be biomechanically
characterized as an incompressible thin membrane material due to negligible thickness of
the bladder wall during loading, biaxial mechanical testing would more efficiently mimic
the physiological bladder loading (109). For this reason, we performed preliminary
biaxial testing of acellular PCUU scaffolds with assistance from CellScale technical staff.
The stretch ratio (deformed / original length) of the PCUU scaffolds under equi-biaxial
stress of 100 kPa were estimated to be 1.09 ± 0.03(X-axis) and 1.11± 0.04 (Y-axis) for
normal PCUU and 1.14 ± 0.04 (X-axis) and 1.17 ± 0.03(Y-axis) for compliant PCUU,
respectively (Figure 5). These values are in the same range as the biaxial stretch values of
native bladder, which were reported to be 1.09 (X-axis) and 1.10(Y-axis) at 100kPa equibiaxial stress (109). The results from these tests demonstrated the anisotropic nature of
the PCUU scaffolds was similar to that of soft tissue organs such as the urinary bladder
under physiological conditions (92), which may be further altered by varying
electrospinning conditions. The results of biaxial testing also provided evidence that both
types of PCUU (normal and compliant) displayed the areal strain under 100 kPa
equibiaxial stress that were slightly lower (normal-0.13, compliant-0.21) (Figure 6) than
that of native rat bladder (~0.28) reported previously by Gloeckner et al (109). It should
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be noted, however, that the values reported by Gloeckner et al. were obtained after
subjecting the native bladder to pre-conditioning wherein the first nine loading-unloading
cycles were performed to stabilize the tissue mechanical responses for reproducibility
(109).Thus, the freshly harvested bladder (close to in vivo state)would have been stiffer in
the absence of preconditioning and would be further closer to the range of the stiffness of
the PCUU scaffolds in this experiment.
LIVE/DEAD and rhodamine-phalloidin staining of BSMC indicated high viability
(more than 90% ) (Figure 6A) and elongated, spindle like morphology of BSMC
indicating that the scaffold conditions could support native smooth muscle phenotype
(Figure 6B). The immuno-staining results indicated maintenance of contractile smooth
muscle cell markers by the BSMC seeded on the surface of PCUU scaffolds at the end of
7 days (Figure 7). Thus, PCUU indicated its cytocompatibility as scaffold to maintain
contractile smooth muscle phenotype in vitro. The maintenance of contractile phenotype
is important for the successful outcome as an engineered tissue because BSMC have a
tendency to differentiate into synthetic / proliferative phenotype (19). Synthetic smooth
muscle cells produce excessive amount scar tissue that will decrease compliance and
eventually reduce functional bladder volume and increase urinary storage pressures (12).
The pressure-volume experiments of the PCUU-sutured bladder were conducted
using our custom ex vivo pressure device, which was originally used in other studies of
our group to determine the adhesive sealing strength in bladder puncture wounds (110).
The previous study demonstrated that the maximum pressure the samples could withstand
were 225 ±52.9 cmH2O, for whole bladders and up to 100±5.4 cmH2O for adhesive76

sealed ones (110). In the present study, the PCUU sutured bladders could withstand
pressure up to 60 cmH2O before saline started to leak from the defects around the sutures,
which prevented us from quantifying the rupture pressure. The results of the pressurevolume experiments showed that the PCUU sutured bladders exhibited an elastic region
similar to that of the intact bladder, and had a reduced capacity and shorter toe region
compared to the control. The PCUU scaffold did not display unusually high stiffness at
low forces and withstood peak stress the bladder experiences typically in the human body
and thus, indicated its suitability to be used as a urinary bladder scaffold. We discovered,
however, that these experiments were extremely difficult to obtain reproducible data
because of poor tissue integrity and leaking of saline from the puncture wounds created
during suturing. Although we attempted to seal puncture wounds with cyanoacrylate
(super glue), this resulted in stiffening of the bladder-scaffold construct and inaccurate
pressure-volume reading.
The SEM imaging results showed that the PCUU scaffold is porous and
conducive for BSMC to grow and proliferate. The fibers align along the direction of
stretch naturally and increase in stretch lead to increase in porosity, which is conducive
for BSMC to infiltrate the scaffold under physiological loading conditions. It should be
noted, however, that the percent porosity was analyzed semi-quantitatively using the
SEM images and image analysis software unlike conventional approaches to measure the
physical porosity by mercury intrusion and ethanol displacement techniques (20). Hence,
the percent porosity of PCUU scaffolds calculated in the present study (37.6 ± 3.9 % to
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57.1± 2.8%) was not directly comparable to % porosity of PCUU (84±4 %) as reported in
previous studies by Hasizume et al. (20).
The SEM imaging also revealed that the pore diameter in the PCUU scaffolds is
between 5-20 µm across the scaffold. This is lower than the pore size (35-70 µm)
typically necessary to promote angiogenesis (111) and hence the current version of
PCUU is unsuited for encouraging capillary infiltration into the scaffold in vivo. Several
studies have shown that time period and depth of vascular ingrowth into the biomaterial
implanted may depend on pore size (112). One method to increase pore size would be to
increase the amount of media (DMEM +10% Fetal Bovine Serum +10% horse serum +
5% penicillin/streptomycin) electro-sprayed onto the scaffold while it is being
electrospun to loosen up the fibers while fabrication. The pore size and % porosity can
also be increased by increasing the mandrel translation speed during the electrospinning
process. Previous studies have shown that an increase in mandrel translation speed
corresponded to a decrease in fiber intersection density and the formation of a more open
structure in PEUU scaffolds (107).
In summary, comparison of mechanical behaviors of biodegradable elastomeric
scaffolds demonstrated that the PCUU scaffolds mimic urinary bladder mechanics most
effectively compared to PGS-PCL and PEUU. The PCUU scaffolds exhibit relatively
high compliance under low forces and are able to withstand stress corresponding to 100
kPa and, thus, possess the strength and stiffness necessary to be used for urinary bladder
tissue engineering. The PCUU scaffolds also showed cyto-compatibility to maintain the
contractile phenotype of BSMC and increased porosity with increasing stretch indicating
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its ability to aid in infiltration of smooth muscle cells. Hence, the PCUU scaffolds were
selected to be tested in our custom-made bioreactor and in vivo studies for further
characterization towards bladder tissue engineering applications.
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Chapter 5
CUSTOM-MADE BIOREACTOR FOR CONDITIONING OF BSMC SEEDED
PCUU SCAFFOLDS
Introduction
The results reported in Chapter 4 demonstrated that electrospun, wet PCUU
scaffolds exhibit mechanical behavior similar to that of the human bladder and displayed
BSMC cytocompatibility. Moreover, the immuno-staining of the BSMC seeded on top of
the PCUU scaffolds indicated expression of α-actin (early SMC marker) and SM1 and
SM2 (smooth muscle myosin heavy chain contractile phenotype marker) (Figure 4-6).
However, there is tendency of functional contractile bladder smooth muscle cells in
culture to de-differentiate into a synthetic, proliferative smooth muscle phenotype (55).
Previous work by our group demonstrated that when exposed to sustained tension, BSMC
seeded in collagen gels expressed a significantly greater level of contractile phenotypic
marker proteins (a-SMA and SM22) and a more elongated and spindle shaped
morphology compared to BSMC seeded in collagen gels without tension (62). Based on
these results, the goal of the present study was to examine the effect of controlled tension
loading conditions on the BSMC on the PCUU scaffold.
A number of studies have investigated the effect of mechanical forces by
bioreactors on cells seeded on bladder scaffolds. Human smooth muscle cells on a
flexcell device (FX-3000 , Flexcell International) were exposed to simulated bladder
filling and voiding of a five year old child via step-by-step elongation and relaxation (1%
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increase every 5 min 12 s during a period of 104 min) for a period of 10 days (113).
However, this step-wise loading did not resemble physiological bladder filling and
emptying and hence, led to reduction in cell growth. A slight improvement in cell growth
was achieved by the coating of the ECM protein laminin. Thus, the study indicated that
coating scaffolds with ECM proteins like laminin and then subjecting it to physiological
bladder tension would aid in the maintenance of BSMC viability and growth.
Our custom made bioreactor was designed to expose cells on scaffolds to various
loading conditions to mimic bladder cycling, the process of sequential expansion and
contraction, characterized by the filling, storage and evacuation of urine in the bladder
(114). Our bioreactor has the ability to subject the scaffold to continuous pre-determined
stretch, maintain the stretch for a fixed time-period and ramp down to the pre-load length
similar to the filling, storage and evacuation of urine in the body, mimicking cycling.
Cycling, triggered by the production of urine, begins in utero and is important in the
anatomic and physiologic development of the normal bladder (114). BSMC in the body
rely upon mechanical stimuli as feedback (mostly coming from the supporting matrix) for
replication (7). Hence, stretch mimicking physiological conditions in vivo will aid in
promoting BSMC proliferation and growth.
Previous bladder tissue engineering studies using bioreactors have been limited to
subjecting the scaffolds to no more than 25% stretch (115), although the urinary bladder
under physiological conditions expands to more than 100% during filling (116). To
address this issue, the present study attempted to expose BSMC-seeded PCUU subjected
to 25-75% stretch using our custom-made bioreactor. To aid in the continued attachment
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of BSMC onto the scaffold during mechanical loading, the PCUU scaffolds were coated
with gelatin and fibronectin to provide cell –adhesion sites to form PCUUFN-G scaffolds.
We performed two experiments to characterize the cytocompatibility and effectiveness of
the PCUUFN-G. First we characterized BSMC morphology inside PCUUFN-G, using
histology on 7 and 21 day time –periods after cell seeding, to determine the extent of cell
penetration. We then characterized the cell morphology and phenotype of BSMC
subjected to stretch (1.25 for three hours) 7 days after cell seeding.
Materials and methods
BSMC seeding on PCUU
The PCUU scaffolds are placed in scaffold shaped defects on
polydimethylsiloxane (PDMS) films formed on glass dishes. The PCUU scaffolds (~2
mm × 20 mm) were sterilized by soaking in 70 % ethanol for at least 1 hr and then
washed thoroughly with sterile Dulbecco’s phosphate buffered saline (DPBS) before cell
seeding. The scaffolds are then soaked overnight in BSMC culture media composed of
RPMI supplemented with 10% FBS and 1% antibiotic/antimycotic. The BSMC was
suspended in 20-25 µl of BSMC culture media at a final concentration of ~1 × 105
cells/scaffold and seeded evenly at 4-5 places on each scaffold (the scaffolds were neither
too wet or too dry while seeding the cells). The cells were allowed to attach to scaffolds
for 1-1.5 h before flooding the culture plate with additional medium. After incubation
under standard cell culture conditions (humidified, 37 °C, 5% CO2 / 95% air) overnight,
the cell-seeded scaffolds were transferred to new well plates with fresh media to separate
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them from the cells attached to the bottom of PDMS wells. BSMC after three passages
were seeded on PCUU scaffolds for immuno-staining experiments.

Bioreactor
The tension-controlled bioreactor was previously designed and assembled by
members of Nagatomi lab to expose hydrogel-based 3D cell culture constructs to
prescribed tensions in vitro. Briefly, it consists of two channels capable of subjecting
specimens (~ 2 X 20 mm) to uniaxial tensile loading with a stepper motor (Haydon Kerk
Motion Solutions, Waterbury, CT) and load cell (LCL-113, Omega) on each end of both
channels. The stepper motor is controlled by a driver circuit through custom LabVIEW
(National Instruments) program allowing for precise control of linear displacement,
which simulates bladder filling in vivo. The LabVIEW program controls the uniaxial
displacement via five major input parameters: loading rate, unloading rate, number of
cycles, time target and desired stretch. The bioreactor is designed to operate in cell
incubator conditions of 37°C and 5% CO2 and device components can be sterilized by
UV radiation.
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A

Fig 5-1: Custom made bioreactor (A) subjecting the PCUU scaffold (B) to stretch.
The Bioreactor subjected the PCUU scaffold to 25% stretch for one cycle (3 hours) in
cell culture media.

Coating of PCUU scaffolds with Fibronectin-Gelatin films
Layer by layer (LBL) technique by alternate immersion of scaffolds into FN and
gelatin solutions was used to form controlled nanometer-sized thin films on each PCUU
fiber. Due to interactions with α5β1 integrin receptors on the cell surfaces, LBL preparation
of FN-G films were intended to provide adhesive polymer scaffolds for cells without
serious disruption of surface structure. Briefly, the PCUU scaffolds were immersed in 0.04
mg/ml fibronectin (FN) (Mw = 4.6 × 105, Sigma-Aldrich) and 0.04 mg/ml gelatin (G) in
50 mM Tris-HCl (pH = 7.4) for 2 min each for the preparation of FN-G films on the
scaffolds. After each procedure, the PCUU was washed with 50 mM Tris-HCl (T) (pH =
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7.4 after one min. After twenty one steps of immersion, (FN/G) 10 FN films were prepared
onto the scaffold to form PCUUFN-G scaffolds.

Stretch Experiments:
PCUU scaffolds (thickness: 0.1~0.2 mm) were prepared with dimensions ~ 2 X
20 mm and seeded with BSMC at a concentration of 3 X 105 cells/ scaffold. Cell-seeded
PCUU scaffolds were cultured in RPMI supplemented with 10% FBS and AB/AM for 7
days and then mounted in the bioreactor. Each specimen was subjected to a uniaxial
loading over three hours which included one hour of ramping up, one hour of maintaining
the maximum stretch (1.25, 1.5, or 1.75), and one hour of ramping down to the pre-load
length (Figure 5-2). Each cycle was designed to mimic the gradual stretching the bladder
wall tissue during filling followed by voiding (117). However, gradual ramping down,
instead of simulated voiding phase was used to avoid cell detachment from the scaffold
due to sudden change in the length. The maximum stretch was determined based on the
values for bladder filling reported in the literature (116).
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Figure 5-2: Representation of PCUU specimen subjected to 75% stretch for one
cycle using the LabVIEW program. The cycle consists of 1 hour of ramping up, one
hour of maintaining the maximum stretch (1.75), and one hour of ramping down to the
pre-load length

Immuno-staining of BSMC seeded PCUU Scaffolds
The BSMC in the PCUUFN-G scaffolds was examined by immuno-staining for a smooth
muscle cell phenotypic marker smoothelin. Briefly, the PCUUFN-G scaffolds were fixed
for 20 min and then blocked using a solution composed of 2% bovine serum albumin, 3%
goat serum, prepared in PBS. After triplicate washes with PBS, the PCUUFN-G specimens
were incubated with primary anti-bodies for mouse smoothelin (1:100 dilution, Thermo
scientific, USA ) and then incubated at 4ºC overnight. The PCUUFN-G scaffolds were
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then incubated with the secondary antibody Alexa-fluor 488 Anti-Mouse IgG (H+L)
overnight, followed by nuclear staining with DAPI for 5 minutes.
Histological examination
The fixed samples were embedded in Richard Allen ScientificTM NEG 50TM
(Frozen section medium, Thermo Scientific, USA) and frozen using Freeze Spray
(Chemtronics, GA, USA). Serial sections were generated at thicknesses of 8 μm on a
Microm HM505 N cryostat for conventional histology. The specimens were then imaged
using laser confocal microscopy (C1Si Confocal; Nikon Ti Eclipse).
Results and Discussion
Stretch Experiments
Initially in all stretch experiments, the BSMC detached from the PCUU scaffolds
after subjection to 25%, 50% and 75% stretch. We hypothesized that the PBS wash after
sterilization was not enough to promote BSMC spreading and infiltration. Thus, the
PCUU scaffolds were seeded with BSMC after 1 day in RPMI 1640 + 10% FBS + 1%
AB/AM for ECM protein absorption onto the constructs. The Soaking of scaffolds in
serum containing medium helped cells adhere better (Figure 5-3) to the PCUU construct.
However, this did not prevent cells from lifting off the PCUU scaffold once it was
subjected to stretch. Based on these results, we proceeded to use the layer by layer
method to coat the scaffold with gelatin and fibronectin to assist in BSMC adhesion
during the stretch cycle. The layer by layer coating of the PCUU constructs in previous
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studies of our laboratory demonstrated that the protein coating did not affect the surface
structure of the PCUU scaffolds by SEM imaging where uncoated PCUU scaffolds had
the same fiber diameter as the PCUUFN-G scaffolds. The cells continued to adhere to the
PCUUFN-G after 25% stretch for one cycle (Figure 5-5).

Figure 5-3: Cell adhesion on PCUU scaffolds soaked in cell culture media.The
presence of RGD proteins in RPMI 1640 aided in cell adhesion throughout the scaffold.

Immuno-staining and histological examination of BSMC in the PCUU scaffolds
The BSMC infiltration into PCUUFN-G scaffolds increased substantially from the 7
day to 21 day time-point as seen in figure 5-3. The BSMC were present only on the
surface on day 7, but infiltrated uniformly up to ~ 50 µm and up to 60-70 µm into the
scaffold in some regions on day 21.
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Figure 5-4: Cell infiltration in static PCUUFN-G scaffolds.The penetration of BSMC
was deeper inside the PCUUFN-G section after 21 days (B) compared to the 7-day (A)
time-point.The acellular surface (bottom) of the PCUUFN-G scaffolds after 7 days is
denoted by the white line.

The thickness of the detrusor smooth muscle layer in the human body is ~1.3 mm
(73) and hence, based on the rate of BSMC infiltration seen in figure 5-4 (~60 µm in 14
days) , it would theoretically take 303 days for BSMC to actually infiltrate a clinically
relevant scaffold implanted to replace the detrusor in vivo. Thus, to accelerate cell
infiltration inside the PCUU FN-G , different techniques need to be adopted.
Electrospraying BSMC during electrospinning of PCUU can be done to form highly
cellularized PCUU scaffolds, which would drastically reduce the culture time-period
prior to implantion in vivo.This Cell microintegrated technology has been tested in
PEUU scaffolds previously to form conduits for blood vessel replacement and has
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demonstrated vascular SMC viability and cytocompatibility(101) after a four day timepoint after cell spraying (101). Another technique which we could adopt to create
clinically relevant PCUU scaffolds would be to culture BSMC on multiple thin PCUU
sheets stacked one on another. This technique was used in studies by Srouji et al. where
they nourished human bone marrow-derived mesenchymal stem cells seeded individually
on thirty electrospun scaffolds (composed of PCL and collagen to form a stack), cultured
in a dynamic flow bioreactor (118) and showed massive cell proliferation and distribution
inside the scaffolds. Thus, theoretically following this method, we could stack 10-11
BSMC seeded PCUU sheets, culture the stack in a perfusion bioreactor system which
could give us a completely cellularized construct in a period of four weeks which would
eventually be implanted in vivo.

The stretch experiment demonstrated the continued presence of BSMC in
PCUUFN-G scaffolds after 25% stretch for 3 hours. The morphology and distribution of
BSMC seeded on the surface resembled the control scaffold (figure 4B) unlike the
occurrence of BSMC detachment previously.
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Figure 5-5: Immuno-staining of BSMC on the PCUUFN-G scaffold with antibodies
for smoothelin. The PCUUFN-G scaffolds were seeded with BSMC for 1 week and
consequently subjected to one cycle of 25% stretch for 3 hours before immunostaining
are represented in figure A. The PCUUFN-G Scaffolds which are not subjected to stretch
are used as controls (B).

The results of the present study provided evidence that our custom-made
bioreactor could generate accurate linear displacement on a polymer sample for a given
time-period. The novelty of the tension-controlled bioreactor device is the ability to
adjust linear displacement based on the current force monitored by the load cell for a
desired number of cycles though automated functionality. The device could also be used
with a displacement control mode to subject the scaffold to a prescribed maximum
stretch. In the present study, the BSMC seeded PCUUFN-G scaffold was exposed to a
stretch as high as 1.25 without cell detachment. However, the BSMC displayed a round
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morphology and sparse distribution due to the low cell seeding concentration (Figure 55). Based on our rhodamine-phalloidin staining of BSMC on PCUU surface (Figure 4-5)
we could estimate that cell seeding at more than (2 X 106 cells/cm2) could lead to the
creation of cell bundles. Thus, future studies will need to use a higher cell concentration
to increase cell-cell communication and faster cell infiltration throughout the PCUUFN-G
scaffold. Further studies could also focus on the bio-reactor being operated for longer
time-periods and multiple cycles.
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Chapter 6
IN VIVO STUDIES EXAMINING ACELLULAR PCUU SCAFFOLDS IN
BLADDER AUGMENTATION
Introduction
Previously, Atala and colleagues reported successful outcomes of implanting
tissue engineered neo-bladders in both dogs and humans (13, 46). The scaffolds made of
polyglycolic acid (PGA) coated with poly-DL-lactide-co-glycolide 50:50 (PLGA) were
seeded with autologous urothelial cells on the luminal surface and smooth muscle cells
on the exterior surface and cultured for 32 ±2.8 days. Following implantation in beagle
dogs, the neo-bladder was wrapped with the hosts’ omentum for vascularisation (13, 46).
The cell-seeded neo-bladders exhibited capacities and compliance greater than the precystectomy level of the patients’ bladders eleven months post-surgery and the retrieved
tissues displayed a normal cellular organization, consisting of a trilayer of urothelium,
submucosa, and muscle with innervation (46). Based on the success in the pre-clinical
study using dogs, a similar approach for bladder augmentation with engineered neotissue was tested in humans with myelomeningocele needing cystoplasty (13). Among the
types of scaffolds tested, collagen-PGA composite scaffolds with omentum wrapped
exhibited the greatest bladder capacity and compliance. The abnormally high bladder
pressure before the operation clearly improved 10 months after implantation of the neobladder (13). In addition, immunohistochemical analyses of biopsy tissues revealed that
smooth muscle and urothelial cells within the regenerated bladder constructs were
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phenotypically normal (13). The success of the bladder augmentation was limited and
seemed to depend on the presence of omentum, which may or may not be available in all
patients needing bladder replacement. Recent phase II clinical trials by Tengion® was
performed using the autologous cell-seeded collagen-PGA/PLGA to establish the safety
and efficacy of the regenerative biodegradable scaffold for use in bladder augmentation
scaffold for patients (74). Ten patients between age-groups 3 to 21 years with medically
refractory neurogenic bladders were selected for the trial and were monitored for a period
of 36 months. The results demonstrated that compliance improved in 4 patients at 12
months and in 5 patients at 36 months, although the difference was not clinically or
statistically significant. There was no clinical or statistical improvement in bladder
capacity at 12 or 36 months in any patient (74). Adverse events occurred in all patients,
and most were easily treated. Two patients had low cell growth following bladder biopsy,
of whom one withdrew from the study and one underwent a second biopsy. Serious
adverse events of bowel obstruction and/or bladder rupture occurred in 4 patients. These
multiple adverse events without improving capacity or compliance resulted in
discontinuation of the study (74).
A recent, comprehensive review of twenty eight bladder tissue engineering
studies by Sloff M and group concluded that though pre-clinical studies using healthy
animals showed promising outcomes, subsequent clinical trials could not replicate the
results revealing dissimilar outcomes in different clinical/disease backgrounds (119). In
addition, the analysis showed that the proliferation and differentiation capacity of isolated
UCs and SMCs from diseased patients was diminished and altered compared to healthy
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individuals. Thus, to correctly predict the effect of tissue engineering for bladder
augmentation, animal models with dysfunctional bladders have to be evaluated. Hence,
our goal in the present study was to develop a clinically applicable animal model for
evaluation of engineered bladder tissue. Thus, in collaboration with Drs. Todd Purves and
Monty Hughes, Department of Urology, Medical University of South Carolina, we
conducted a pilot study to augment the bladder with a PCUU patch using a rat model of
bladder outlet obstruction (BOO). Bladder outlet obstruction (BOO) is a well-known
bladder dysfunction model induced by benign prostatic hyperplasia or urethral stricture
(120). When there is mild-to-moderate BOO and conservative treatments fail to protect
the upper urinary tract, the only remaining treatment option is surgical reconstruction of
the bladder. To date, the BOO model is the most prominent model for bladder
dysfunction, and other pathologic models are still in early stages of development (120).
BOO is one of the most common problems in elderly males. It is caused by collagen
deposition in the bladder as a result of various pathological processes. Eventually, this
collagen deposition results in bladder fibrosis and induces a flaccid, noncompliant
bladder. Bladder fibrosis adversely affects the composition of the bladder wall by
reducing the smooth muscle component, resulting in low bladder compliance (120). Due
to the limitation with resources and surgeon time, only three animals have been studied to
date. During the 21-day implantation period, voiding volume and bladder capacity were
calculated at every 7 day time-period by gavaging the rat with H2O and quantitating the
voids in a custom made metabolic cage and weighing scale. Following sacrifice of the
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animal, histology and immuno-histochemistry were performed to characterize cell
infiltration and calcium deposition.

Materials and methods
Bladder surgery and PCUU implantation
Creation of bladder outlet obstruction and the augmentation surgery were
performed by Dr. Todd Purves of Medical University of South Carolina following a
established protocol. Briefly, for all BOO rats a sterile, lubricated catheter (P50 tubing;
O.D. 1 mm) was inserted transurethrally, the end cauterized and the tubing secured to the
inguinal region using 5-0 PGA suture material. The abdominal cavity was then opened
longitudinally and the urethra identified. 5-0 silk suture material was then passed around
the urethra and tied securely to produce the BOO or tied loosely for Sham BOO animals.
The inguinal stich was then cut and the catheter removed. After a period of 10 days, the
animals are then anesthetized by intra-peritoneal injection of ketamine hydrochloride (90
mg/kg) and xylazine (10 mg/kg) and then shaved to expose the surgical site using a
midline abdominal incision above the pubic bone. A 1 cm-long incision was made at the
dome of the bladder using surgical scissors to create a defect and a square piece (1 cm x 1
cm ) of PCUU scaffold was sutured using a non-absorbable 8-0 nylon suture (n=1) and
absorbable 7-0 Vicryl Sutures (n=2) (Figure 6-1).
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Figure 6-1: in vivo acellular PCUU implantation. A 1x1cm PCUU patch is sutured
onto the day 10 BOO bladder.

Monitoring voiding volume and bladder capacity
At the end of prescribed time-periods (Days 1,7,14, and 21) after PCUU
implantation, the rat voiding volume and bladder capacity was studied by placing the rat
in a custom made metabolic cage (23 x 15 x 23 cm) with a wire mesh bottom above a
scale (mettler toledo, Columbus, Ohio) (Figure 6-2). To ensure that the rat would void
recordable volumes of urine during the experiment conducted in day time, the animal was
gavaged with 500 µl of drinking water prior to being placed into the cage. The reading of
the scale was continuously monitored by a computer with special software (MED-CMG
software, Catamount Research and Development, St. Albans, VT)) which registered the
time and volume of urine voided by the rat. After the urine voids were recorded on each
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day (discounting fecal voiding), the rat was returned to the animal facility. The voiding
volume and bladder capacity of Sham BOO rats (BOO rats without bladder defect
creation and scaffold implantation) , control rats (normal rats with no procedure) , PCUU
day 0 rats (rats with 10 day BOO before defect creation and scaffold implantation) were
also measured by Dr. Monty Hughes, Department of Urology, Medical University of
South Carolina.

Figure 6-2 : Monitoring voiding volume and bladder capacity. The image describes
the custom-made metabolic cage with a wire mesh bottom placed above a monitoring
scale.

Histological analysis of explanted tissues
At the end of three week time period after implantation, the rat was euthanized
using isoflurane (Piramal Healthcare , Andhra Pradesh , India) and the whole bladder was
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harvested. The bladder was then cut in half horizontally and the bladder half with the
patch was placed in neutral buffer saline (NBF) for fixing.The bladder was inverted to
expose the region of the patch , which was cut into four parts for histological and
immunohistochemical analysis. Bladder tissue from control rats (without surgery) and
sham BOO rats (BOO rats without PCUU patch) were also examined. The BSMC in the
PCUU scaffolds was examined by immuno-staining for α-actin and smoothelin. Briefly,
the PCUU scaffolds were fixed for 20 min and then blocked using a solution composed
of 2% bovine serum albumin, 3% goat serum, prepared in PBS. After triplicate washes
with PBS, the PCUU specimens were incubated with primary anti-bodies for mouse
smoothelin (1:100 dilution, Thermo scientific, USA) and α-actin (1:100 dilution, SigmaAldrich, USA) and then incubated at 4ºC overnight. The PCUU scaffolds were then
incubated with the secondary antibody Alexa-fluor 488 Anti-Mouse IgG (H+L)
overnight, followed by nuclear staining with DAPI for 5 minutes. To create frozen
histological sections the fixed samples were embedded in Richard Allen ScientificTM
NEG 50TM (Frozen section medium, Thermo Scientific, USA) and frozen using Freeze
Spray (Chemtronics, GA, USA). Serial sections were generated at thicknesses of 8 μm on
a Microm HM505 N cryostat for conventional histology on glass slides. Other speciments
were stained with Hematoxylin and Eosin (H& E), Masson’s Trichrome and alizarain
red based on standard protocols after obtaining frozen sections on glass slides. All the
staining techniques were performed using well established protocols for frozen sections.
Briefly, the H& E stain consists of hemotoxyin which is a basic dye (positively charged)
which stains the nuclei blue and Eosin which is a acidic dye (negatively charged ) which
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stains the cytoplasm and other tissue elements in various shades of pink. The Masson’s
trichrome staining is used mainly for the detection of collagen fibers which is stained
blue, nuclei which is stained black and muscle,cytoplasm and keratin which is stained
red. The alizarain red stains the calcium deposits in the scaffold in an orange-red color.
Results
Monitoring Voiding volume and bladder capacity
The results of the present study provided evidence that the mean voiding volume
remained similar on day 0 (639.43 ± 239.48 µl) (n=3), day 1 (635.21 ± 391 µl) (n=3) and
day 7 (638.64 ± 413.33 µl) (n=3) followed by a increase on day 14 (815.65 ± 210.45
µl)(n=2) and day 21 (968.75 ± 592.83 µl) (n=2). The control rats had a mean voiding
volume of 871.87 ± 166.14 µl (n=2) and the sham BOO rats had a mean voiding volume
526.9 ± 318.15 µl (n=5). The time span for 8 voids was 8308 ±5359 seconds on day 1,
followed by a decrease on day 7 (7612 ± 700 seconds), leading to a gradual increase on
day 14 (9973±1453 seconds) and day 21 (10,130±10533 seconds) surpassing the time
span of day 1. The control rats did not void more than 4 times 1.5-3 hours after gavaging
and the sham rat took 3963.625 ± 755.72 seconds for 8 voids(n=2), with the remaining
two rats not voiding more than 6 times even after 2.5 hours. The maximum voiding
(bladder capacity) followed a slightly different pattern as the mean voiding volume where
similar values were obtained on day 1 (maximum: 1506 µl, minimum: 313 µl) and day 7
(maximum:1576µl, minimum : 226 µl) followed by a decrease on day 14
(maximum:1167 µl, minimum: 505µl) and a subsequent increase (maximum:1997 µl,
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minimum: 230 µl) on day 21 (Table 1).the maximum and minimum voiding values of
control and sham BOO rats were (maximum: 1163 µl, minimum: 595 µl) and
(maximum: 1414 µl, minimum : 200 µl) respectively (Figure 6-3).

Sample

Number of specimens

Maximum Capacity (µl)

Average voiding volume (µl)

Control

2

1163

871.88 ± 166.14

Sham BOO

4

1414

526.9 ± 318.15

PCUU Day 0

3

1371

639.43 ± 239.28

PCUU Day 1

3

1622

635.21 ± 390.55

PCUU Day 7

3

1576

638.64 ± 413.33

PCUU Day 14

2

1167

815.65 ± 210.45

PCUU Day 21

2

1997

968.75 ± 592.83

Table 6-1: Measurement of micturition for various samples tested.
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Figure 6-3: Measurement of micturition values. The voiding volume on urine voided
by rats for different samples. Values are mean ± SEM; n=2 for control bladders, PCUU
Day 14 and 21; n=4 for sham BOO rats; n=3 for PCUU Day 0, 7 and 14.

Morphology and histological analysis
The implanted PCUU scaffold was visible on inspection of the exterior of the
augmented bladder upon harvest (Figure 6-4A). Caliculi were clearly visible throughout
the inner lumen of the bladder (Figure 6-4B). The PCUU scaffold remained intact for the
21 day period and based on its white color clearly distinguishable from surrounding
tissue inside the bladder lumen . H&E stained sections of the explanted PCUU scaffold
revealed smooth muscle cell infiltration indicated by eosin (pink) for the cytoplasm of
muscle cells and connective tissue cells or fibroblasts indicated by a light purple
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(haemotoxylin) for cell nuclei (Figure 5A). Unlike the control explant (figure 5B and
5H), the sham BOO explant (Figure 5C and 5I) indicated the presence of possibly
immune cells indicated by the black dots in the muscle layer. The intense red color of
Alizarin Red staining indicated that the PCUU specimen was infiltrated with calcium
deposits (Figure 5D) which was nearly absent in the control and sham specimens (Figure
5E and 5F). The masson’s trichrome staining indicated an acute inflammation in the
PCUU explant indicated by the presence of nuclei (black) representing fibroblast and
macrophages in the scaffold (Figure 5G). The immuno-staining for ɑ-actin and DAPI
indicate presence of cells throughout the scaffold (Figure 5K) and infiltration of smooth
muscle cells limited to the surface of the scaffold in contact with bladder tissue was
demonstrated by immuno-staining for smoothelin and DAPI (Figure 5N).The negative
control specimen with no primary antibody (ɑ-actin and smoothelin) proved the absence
of non-specific binding of the α-actin and smoothelin antibodies and indicated only the
presence of DAPI staining (Figure 5P). The control and sham BOO explants demonstrate
the presence of smooth muscle cells throughout the sections when stained for ɑ-actin
(Figure 5L and 5M) and smoothelin (Figure 5N and 5O ) respectively.
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A

B

Figure 6-4 : Augmented Bladder removal after 21 days. The presence of the PCUU
scaffold (A) and calcium depositions (B) is indicated by the black arrow.
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Figure 6-5: H& E staining of PCUU scaffold (A), control bladder (B) and sham
BOO bladder (C) tissue sections, Alizarin red staining of PCUU scaffold (D) control
bladder (E) and sham BOO bladder (F) tissue sections and Masson’s Trichrome
staining of PCUU scaffold (G) , control bladder (H) and sham bladder (I) tissue
sections at 40X magnification.Immuno-staining for ɑ-actin and DAPI on the PCUU
scaffold (J), control bladder (K) and sham bladder (L) tissue sections , Immunostaining for Smoothelin and DAPI on the PCUU scaffold (M), control bladder (N)
and sham BOO bladder (O) tissue sections along with PCUU scaffold with no
primary antibody (P) at 40X magnification. The PCUU scaffolds demonstrated
scattered pink (eosin) staining indicating cytoplasm in muscle cells and a light purple
(haemotoxylin) indicating nuclei of connective tissue or fibroblasts. The Masson’s
trichrome staining indicated red (muscle) , blue (collagen) and nuclei (black) .The PCUU
scaffolds demonstrated the orange-red coloration indicating calcium deposits.The PCUU
scaffold , control and sham bladder demonstrated the presence of cellular cytoskeleton
(green) and nuclei (blue) in the sections. The absence of primary antibody showed only
DAPI staining indicating that the green coloration was not non-specific binding. The
orange arrows indicate the PCUU explant attached to rat bladder tissue.
Discussion
Although the sample size was limited to two successful animals, the present pilot
study of in vivo bladder augmentation provided a large amount of valuable information,
which could not have been gained from in vitro studies alone. First, it demonstrated that

106

augmentation of the bladder with a PCUU scaffold led to extension of the BOO rats
survival (66 % survival rate was observed 31 days after BOO), which otherwise is limited
to 1 - 2 weeks. Second, the rat BOO model provided a platform of bladder dysfunction
for which functional changes could be monitored. In addition, we found that the BOOinduced hypertrophy of the bladder made it easier for augmentation.
BOO bladders are overactive bladders typically charcterized by high bladder
pressure and low urine flow rate usually accompanied by small voided volume of urine.
In our study, PCUU day 1 was characterized by bloody voids due to surgical insult to
tissue followed by healing by day 7. However,the voiding volume measurements
demonstrated that mean voiding volume and bladder capacity increased with time and
was highest for the PCUU day 21 compared to the mean voiding volume and bladder
capacity for PCUU day 1, control and sham BOO (Table 1). In rats, bladder tissue
engineering leads to a larger bladder volume after treatment due to the high regenerative
capacity of the rat bladder, in that even after subtotal cystectomy without augmentation,
the bladder volume recovers completely (119). However, Eberli et al. have reported that
canine BSMC and urothelial-seeded collagen-PGA scaffold implanted subcutaneously in
athymic mice demonstrated a scaffold tissue shrinkage at the 4 week time point compared
to the 2 week time point (47). The volume reduction is attributed to the degradation of
PGA-fiber loops with time (47). Contrary to their report, the PCUU scaffold in our study
did not result in shrinking within the three-week time period. Also, the scaffold did not
lead to scar tissue formation at the end of three weeks.
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The results of histological analysis provided evidence that cell infiltration after 3
weeks of implantation was limited to smooth muscle cells near the edge of the PCUU
construct and other connective tissue cells, fibroblasts sparsely populating the rest of the
scaffold. This was further confirmed by the immuno-staining of specimens where
presence of cell nuclei and α-actin throughout the scaffold and smoothelin on the
extremities of the scaffold were observed. The relatively slow smooth muscle cell
infiltration into the PCUU would potentially lead to slower integration into the host
tissue. To improve the rate of smooth muscle regeneration in the scaffold, it may be
beneficial to pre-seed PCUU scaffolds with BSMC before implanting onto rat bladders.
Previous studies by Zhang et al. have demonstrated that human BSMC- and urothelialseeded SIS scaffolds displayed progressively organized tissue regeneration compared to
acellular SIS scaffolds (51) when implanted in nude mice. However, in diseased bladders
there is a lack of healthy, accessible cell source within the human population. The
autologous BSMC also have a prolonged cell expansion time (67). Hence, several studies
are focusing on the use of adipose derived stem cells (ADSC) instead of autologous cells.
Studies by Jack et al. have shown the ability of ADSC to differentiate into functional and
contractile smooth muscle cells after 12 weeks of implantation when seeded in adult
female Rnu athymic rats (67). However, the regenerated bladders in the study by Jack et
al. displayed signs of bladder caliculi (67) similar to the calcium deposits seen in the
PCUU scaffold implantation of the present study. The cause of stone formation on
scaffolds in the bladder is only partially understood at this point. Studies by Seth and
colleagues have shown that silk-based scaffolds implanted in rat bladders for a period of
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10 weeks also exhibited the presence of calculi (121), but the extent of bladder calculi
formation was dependent on the processing method used for silk scaffold construction.
On the scaffolds fabricated by solvent-casting/salt-leaching method in combination with
silk film, casting stones formed in lesser frequency and smaller diameter than those
fabricated by gel spinning technique. In addition, they demonstrated that the more
compliant the silk scaffolds were, the lower the percentage of calcium stone formation
was displayed (121). However, when we compared the most compliant version of their
silk scaffold (maximum elongation 197±4 % (121)) to our PCUU scaffold (maximum
elongation 243±26 %), it appears that mechanics of PCUU may not be the cause for
caliculi formation in the present study. Another possible reason for the formation of
caliculi was the use of non-absorbable sutures, which we used in the first rat for
implanting PCUU. However, similar calcium depositions were found when we used
absorbable sutures for surgery in two other rats. Thus, in our case, the formation of
calcium stones would be motivated by the substantial insult to the bladder tissue while
suturing (causing bloody voids within the first week) leading to bladders inability to
empty itself fully. Although the formation of caliculi can also be considered as inherent
drawbacks of augmentation cystoplasty in rat models (121), the rat model has several
advantages which include low cost of purchase and maintenance and rapid regeneration
of the bladder upon surgery. However, to gain more clinically relevant data and FDA
approval of the bladder tissue engineering scaffold, it is necessary to conduct large
animal testing as the bladders of large animals such as pigs resemble the mechanics
(ultimate tensile strength and elastic modulus) and ECM composition (Higher density of
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type III collagen and lower density of type I collagen) of human bladders (50). In
addition, in dogs and pigs, normal bladder capacities are reached after augmentation
unlike rats and rabbits where surgery leads to larger bladder volume and bladder stones
(119).Thus, future in vivo studies should focus on developing a pig BOO model to
evaluate the PCUU technology and further advance bladder tissue engineering .
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Chapter 7
Conclusions
7.1 Tetronic-based Composite Hydrogel scaffolds seeded with Bladder Smooth
Muscle Cells for Urinary Bladder Tissue Engineering Applications
In the present study, we explored tetronic-based composite hydrogel scaffolds
seeded with BSMC for urinary bladder tissue engineering applications. The results of in
vitro experiments demonstrated that the composite hydrogel system provided an
environment for bladder smooth muscle cells to adhere, migrate and secrete ECM,
thereby increasing the construct’s overall strength and stiffness. To date, however,
BSMC-seeded composite hydrogel at the end of the two-week culture is still weaker and
more compliant compared to the native urinary bladder tissue (122). We hypothesize that
culturing the construct for longer time periods after BSMC seeding and addition of
growth factors to the composite hydrogel system would further aid in increasing the
strength and stiffness of the composite hydrogel scaffold. Overall, this was the first study
to explore the use of hydrogel blends composed of Tetronic T1107-acrylate (T1107A) in
combination with type I collagen and HA towards applications in urinary bladder tissue
engineering (122).

7.2 In vitro characterization of biodegradable elastomers for application in bladder
tissue engineering
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We characterized various biodegradable elastomers as scaffolds for bladder tissue
engineering since the mechanical properties of our cell-seeded composite hydrogels were
limited after two weeks of culture. The comparison of mechanical behaviors of these
elastomeric scaffolds demonstrated that the PCUU scaffolds mimicked urinary bladder
mechanics compared to PGS-PCL and PEUU. The PCUU scaffolds exhibit relatively
high compliance under low forces and are able to withstand stress corresponding to 100
kPa (super physiological peak stress experienced by urinary bladders in vivo) and thus,
possess the strength and stiffness necessary to be used as a urinary bladder tissue
engineering scaffold. The PCUU scaffolds also showed cyto-compatibility as well as
increased porosity with increasing stretch indicating its ability to aid in infiltration of
smooth muscle cells. Based on these findings, PCUU scaffolds were selected for
subsequent studies using our custom-made bioreactor and an in vivo rat model for further
characterization toward bladder tissue engineering applications.

7.3 Custom-made Bioreactor for conditioning of BSMC seeded PCUU scaffolds
The BSMC seeded PCUU scaffold was subjected to uniaxial mechanical stretch
mimicking bladder cycling using our custom made bioreactor under standard cell culture
conditions (37 °C, humidified, 5% CO2 / 95% air). The BSMC seeded PCUU scaffolds
when subjected to uniform and continuous stretch (1.25-1.75) uni-axially did not undergo
failure in spite of high stretch and indicated its suitability to be used in vivo. Our study
could enhance BSMC adhesion and infiltration into the PCUU scaffold with time by
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coating the scaffolds with proteins (fibronectin and gelatin) using the layer by layer method
(113) and could demonstrate the continued adhesion of the BSMC after a cycle of stretch
(1.25). Future experiments, can characterize the BSMC seeded PCUU in multiple cycles
and higher values of stretch (closer to maximum physiological stretch). Overall, the study
tried to characterize PCUU in conditions mimicking bladder cycling and indicated its
suitability for in vivo experimentation.

7.4 In vivo study examining PCUU scaffolds in bladder augmentation
Despite early promises of bladder tissue engineering, a recent report of
unsuccessful clinical trials (74) suggests that the technology needs further improvement
and evaluation through animal models of bladder dysfunction (119). Thus, our in vivo
study was an attempt at implanting electrospun fibrous PCUU scaffolds onto a bladder
outlet obstruction (BOO) rat model to create a clinically informative study. The BOO
bladders tend to exhibit overactive bladder symptoms with high pressure and voiding
frequency and, if untreated, can often lead to death of the rats due to vesicoureteral reflex.
The PCUU implantation led to the enhanced survival of the rats (66.66%) and increased
bladder capacity and voiding volume with time, indicating that the high pressure bladder
symptom was alleviated. The histological analysis of the explanted scaffold indicated
some smooth muscle cell and connective tissue infiltration, but also calcium deposits. We
hypothesize that ECM-coating and pre-seeding PCUU scaffolds with cells can aid in
promoting faster scaffold integration into the host bladder. Due to inherent tendency of
stone formation in rat models, future studies may switch to using dysfunctional bladder
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models of larger animal like pigs. However, the present study is one of the first to analyze
a synthetic bladder scaffold using a bladder dysfunction model in rats for application in
urinary bladder tissue engineering.

7.5 Summary
The present study characterized composite hydrogel and elastomeric scaffolds for
bladder tissue engineering applications. Based on the results of in vitro mechanical
characterization and cell culture studies, we concluded that PCUU scaffolds were the
most ideal among the ones we examined. For the first time, we used an established rat
model for studying bladder dysfunction (BOO) to evaluate the effect of augmentation of
the bladder with PCUU scaffolds on bladder capacity and voiding volume. However,
further research as recommended below is necessary to advance our understanding of
PCUU scaffolds to ultimately aide in the treatment of bladder disorders.

7.6 Limitations of the Present Study and Future Project Recommendations
o Limitation: The BSMC seeded composite hydrogels do not possess the strength
and stiffness of the native urinary bladder
o Recommended solution: The strength and stiffness of the composite
hydrogels may be improved by promoting cross-linking of the newly
synthesized collagen by culturing the composite hydrogels for longer time

114

periods and/or in the presence of soluble chemical compounds such as
insulin and TGF-β1.
o Limitation: The investigation of the effect of stretch on BSMC-seeded PCUUFN-G
scaffolds using our custom made bioreactor was limited to results from 25%
stretch conditions due to extensive cell expansion time required to obtain rat
BSMC
o Recommended solution: Adipose derived stem cells (ADSC) and other
adult stem cells can be used as an alternate cell source as it is multipotent,
easy to procure, vastly available and has been shown to differentiate into
smooth muscle cells.
o Limitation: The cell infiltration into the PCUU scaffolds after 3 weeks of
implantation was limited to smooth muscle cells near the edge of the PCUU
construct and fibroblasts sparsely populating the rest of the scaffold.
o Recommended solution: Pre-seeding PCUUFN-G scaffolds with
ADSC/BSMC before implantation will help in reducing fibroblast
ingrowth and the neo-smooth muscle tissue would aid in integrating with
smooth muscle layer of host animal
o Limitation: The presence of calcium deposits in the PCUU scaffold because of
the propensity of the rat bladders to form caliculi
o Recommended solution: Although caliculi formation is an inherent problem
with the rat model when implanted with a scaffold, some steps can be taken
to further minimize it. As reported in the study by Seth et al., increasing the
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compliance of PCUU FN-G scaffolds further may reduce caliculi formation
after implantation(6). This can be achieved by increasing the media added
to the pre-electrospun PCUU mix. As an added benefit, the increased
compliance will further bring down the mechanical mismatch with the
native bladder and lead to more efficient removal of urine from the bladder.
Moreover, pre-seeding PCUUFN-G scaffolds with ADSC/BSMC can form a
neo-smooth muscle layer before the scaffold is implanted into the body and
may integrate more efficiently into the bladder and help reduce stone
formation. The caliculi formation can also be reduced by various anticalcification treatments. Future experiments can be performed in the PCUU
sutured bladders where disodiumethylenediaminetetraacetic acid (EDTA)
can be loaded in PLGA nanoparticle pellets and placed periadventitially to
minimize caliculi formation as shown in studies by Lei et al. where
controlled release of EDTA led to regression of elastin specific calcification
in the aorta (123).
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